We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Income investors certainly have a lot of choice on the Australian share market. So much so, it can b...
Read ArticleHighlights Enhanced understanding of SCLC subtypes drives tailored treatment approaches. I...
Read ArticleThe market may be nearing a record high, but that doesn't mean there aren't big potential gains to b...
Read ArticleFresh from news of a “complete response” from other clinical trials last week, Imugene has now dosed...
Read ArticleThe ASX200 has been down 0.4% at 8,261 points. Investors reacted with disappointment to the lates...
Read ArticleHighlights First patient has been dosed in the intratumoural combination arm of the OASIS trial....
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) enjoyed an enthu...
Read ArticleIn an Australian first, clinical cancer researcher and developer Imugene will launch its “azer-cel”...
Read ArticleBoth Wesfarmers Ltd (ASX: WES) shares and Sigma Healthcare Ltd (ASX: SIG) shares offer investors exp...
Read ArticleThe Mineral Resources Ltd (ASX: MIN) share price has been volatile in 2024 and is down nearly 45% th...
Read ArticleImugene Ltd (ASX:IMU) has opened the first Australian site for its clinical trial testing a therapy...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a great finish to the week. In afternoon trade, the...
Read ArticleHighlights The first Australian site for the azer-cel Phase 1b trial is now open. Patient recru...
Read ArticleThe Core Lithium Ltd (ASX: CXO) share price is surging higher today. Shares in the All Ordinarie...
Read ArticleMany of Australia's top brokers have been busy adjusting their financial models and recommendations...
Read ArticleASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) endured a tough da...
Read ArticleAussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors ret...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwise...
Read ArticleIt's fair to say that ASX 300 property stock Lifestyle Communities Ltd (ASX: LIC) has not had a grea...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and dropping into the red. In aftern...
Read ArticleClinical-stage immuno-oncology company Imugene is celebrating more than two years’ “complete respons...
Read ArticleASX exchange-traded funds (ETFs) have surged in popularity over the past few years, especially among...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwise...
Read ArticleHighlights In the Phase 1 MAST trial for VAXINIA, a bile tract cancer patient has maintained a c...
Read ArticleThose who own ASX shares face an existential trilemma: how much cash to hold, how to finance new inv...
Read ArticleImugene Ltd (ASX: IMU) shares are having a strong start to the session on Tuesday. At the time of wr...
Read ArticleImugene (ASX:IMU), a clinical-stage immuno-oncology company, has reported a significant achievement...
Read ArticleShares in the embattled Star Entertainment Group Ltd (ASX: SGR) extended losses on Monday and finish...
Read ArticleThe Woolworths Group Ltd (ASX: WOW) share price has dropped 25% since June 2023 and close to 20% fro...
Read ArticleAre you looking to supercharge your portfolio with some big returns? If you are, it could pay to lis...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is wrapping up the trading week on a decidedly sour note this F...
Read ArticleASX slips amid earnings updates and company meetings AGL drops over 6pc after downgrade, while...
Read ArticleThe ASX200 has been down a third of a percent (0.32%) at 8,154 points. Consumer Staples continue...
Read ArticleThe AGL Energy Limited (ASX: AGL) share price fell 6.9% to an intraday low of $10.38 on Thursday....
Read ArticleTwo S&P/ASX All Ordinaries Index (ASX: XJO) ASX healthcare shares are making big moves today fol...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having another relatively poor session on Thursday. In afte...
Read ArticleThe stock market is one of the best places to invest for long-term returns. That's why I'm not afrai...
Read ArticleWoolworths Group Ltd (ASX: WOW) shares had a difficult time on Wednesday and were sold off by invest...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleHighlights Orphan Drug Designation (ODD) has been secured from the US FDA for VAXINIA (CF33-hNIS...
Read ArticleImugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following pos...
Read ArticleAppen Ltd (ASX: APX) shares have been on a meteoric rise, surging 260% higher in just seven weeks....
Read ArticleThe Appen Ltd (ASX: APX) share price is off to the races today. Shares in the All Ordinaries Inde...
Read ArticleDroneShield Ltd (ASX: DRO) shares are rebounding on Wednesday morning after a 7% decline yesterday....
Read ArticleDroneShield Ltd (ASX: DRO) shares have been a top performer this year, soaring 236% into the green t...
Read ArticleIn early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher. A...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a very disappointing...
Read ArticleS&P/ASX All Ordinaries Index (ASX: XAO) stock Cettire Ltd (ASX: CTT) has gained momentum recentl...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleS&P/ASX All Ords (ASX: XAO) shares essentially moved sideways in August, losing just 0.04%....
Read ArticleThe first two blood cancer patients in a US-based trial, who had suffered relapses despite having tr...
Read ArticleThe ASX200 has closed up 0.22% at 8110 after shaking off early losses. Sectors were a hodgepodge...
Read ArticleThe Australian sharemarket made notable strides on Monday, approaching its record closing high, than...
Read ArticleThe ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian...
Read ArticleIn the first session of the week, the Australian sharemarket is experiencing a steady performance, w...
Read ArticleIn the first trading session of the week, the Australian sharemarket is experiencing a downward tren...
Read ArticleWith so many shares to choose from on the Australian share market, it can be difficult to decide whi...
Read ArticleThe ASX200 has been up down 0.12% at 8,082 points, even on the back of Wall Street chalking up solid...
Read ArticleImugene (ASX:IMU) announced promising results from its Phase 1b clinical trial with azer-cel, in p...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decl...
Read ArticleThe DroneShield Ltd (ASX: DRO) share price is leaping higher today despite the broader stock market...
Read ArticleImugene Ltd (ASX: IMU) shares are starting the week with a bang. In morning trade, the ASX All Ords...
Read ArticleImugene’s stock surges on promising Phase 1b results Emyria’s MDMA therapy for PTSD shows quality o...
Read ArticleHighlights Ten patients were enrolled in the Phase 1b trial of azer-cel, divided into two cohort...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highligh...
Read ArticleImugene (ASX: IMU) has announced positive results from a Phase 1b clinical trial using lead candidat...
Read ArticleImugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel...
Read ArticleCettire Ltd (ASX: CTT) shares were hammered last week. Investors were hitting the sell button after...
Read ArticleThis article is part of the daily news updates from FNArena.com. Stay informed with the latest finan...
Read ArticleThis article is part of the daily news updates from FNArena.com. Stay informed with the latest finan...
Read ArticleHighlights Imugene ended the June quarter with over AU$93 million in cash and equivalents, suppo...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is up 2.5% and in new all-time high territory as we near the en...
Read ArticleIf you're building an income portfolio, then it could be worth looking at the ASX 200 dividend stock...
Read ArticleThere's an ASX dividend stock on the market right now that, until very recently, was yielding close...
Read ArticleTelstra Group Ltd (ASX: TLS) stock is regularly viewed as an appealing ASX dividend share to own. Th...
Read ArticleImugene has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of i...
Read ArticleThe S&P 500 Index (SP: .INX) and Nasdaq Composite Index (NASDAQ: .IXIC) reached new all-time h...
Read ArticleThe market is having a bit of a subdued session on Wednesday, but that isn't stopping one ASX roboti...
Read ArticleThe ASX is down 0.3% to 7,807 points heading into lunchtime trade. Telecommunications is the only...
Read ArticleHighlights The first patient in the Phase 1 bile tract cancer trial has been dosed. The trial i...
Read ArticleThe market may have run out of steam on Wednesday, but not all ASX shares are falling. Two that are...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleImugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duc...
Read ArticleHighlights The first patient has received treatment under the intravenous (IV) infusion combinat...
Read ArticleImugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS...
Read ArticleThe ASX200 is set to fall today, influenced by a mixed US market performance on Friday, which itself...
Read ArticleOverseas markets rallied in May on lower bond yields and stabilising inflation prints, but the Austr...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleSpecial Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital s...
Read ArticleInvestors got the chance to get up close and personal with ASX technology and biotech companies in S...
Read ArticleHighlights Under the Phase 1 MAST trial high cohort dose, dosing of first patients has been conc...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleS&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%....
Read ArticlePointsbet Holdings Ltd (ASX: PBH) shares are having a very tough session on Tuesday. In morning trad...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleThere have been a couple of big moves in the betting industry on Wednesday following the release of...
Read ArticleIf you're the type of investor that likes high risk-high reward investments, then read on. That's be...
Read ArticleHighlights Imugene's partnership with Kincell Bio is aimed at accelerating the development of in...
Read ArticleThe ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle Eas...
Read ArticleAfter shedding nearly double what futures had predicted, the ASX200 closed the day 1.8 per cent down...
Read ArticleAustralian anti-cancer company Imugene has stamped a strategic manufacturing deal with Kincell Bio,...
Read ArticleHighlights The strategic manufacturing and process development collaboration involves the sale o...
Read ArticleASX-listed med-tech company Imugene has launched a pivotal expansion study targeting patients with b...
Read ArticleThere’s no surprises on market today, the ASX200 has been down around half a per cent – on par with...
Read ArticleAtomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in...
Read ArticleHighlights Bile tract cancer expansion study opens after the completion of the high dose cohort...
Read ArticleCancer immunotherapy company Imugene Ltd (ASX: IMU) will be expanding its trial for the use of CF33-...
Read ArticleIt's been a decent week for the S&P/ASX 200 Index (ASX: XJO). Since last Thursday, the ASX 200 h...
Read ArticleIf you're not averse to investing in the mining sector and want big returns for your portfolio, then...
Read ArticleHighlights IMU’s CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx to showcas...
Read ArticleIf you owned S&P/ASX 200 Index (ASX: XJO) lithium stocks in 2021 and 2022, you likely enjoyed s...
Read ArticleIf you're in the market for some new ASX 200 shares in April, then it could be worth listening to wh...
Read ArticleAustralian anti-cancer company Imugene has received a patent to protect its unique cancer treatment...
Read ArticleIt was a happy Thursday for the S&P/ASX 200 Inde...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is bouncing back from yesterday's horror session and is pushin...
Read ArticleHighlights A Notice of Grant received from the Chinese Patent Office for IMU’s oncolytic virothe...
Read ArticleClinical stage immunooncology company Imugene (ASX:IMU) has received a Notice of Grant from...
Read ArticleImugene (ASX:IMU) has announced its receipt of a new patent in China. The Chinese regulator – Asi...
Read ArticleImugene Ltd (ASX: IMU) shares are catching the eye on Thursday morning. In early trade, the ASX 300...
Read ArticleChanges to government legislation can impact Aussie businesses. That's why staying abreast of propos...
Read ArticleHighlights CF33-hNIS (VAXINIA) technology has been selected for an oral presentation at the Chol...
Read ArticleImugene has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “o...
Read ArticleClinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical tria...
Read ArticleDimerix ACTION3 Phase 3 trial successfully passes first interim analysis endpoint Mesoblast says US...
Read ArticleHighlights Phase 1 clinical trial of onCARlytics has moved to the combination arm based on the r...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleA medical mission to flesh out and kill cancerous tumours in humans has received a boost after Imuge...
Read ArticleASX 200 tech stock Data#3 Limited (ASX: DTL) is floundering on Thursday, down 10.79% to $8.73. Th...
Read ArticleHighlights The first patient has been dosed in the intravenous monotherapy arm of the Phase 1 on...
Read ArticleClinical stage immuno-oncology company Imugene (ASX: IMU) has dosed the first patient in the intrave...
Read ArticleASX to bounce back after a tech rally in New York Lyft jumps 35pc despite hiccup in earnings r...
Read ArticleHighlights Positive early signs reported in Phase 1 MAST trial of VAXINIA. VAXINIA received Fas...
Read ArticleHighlights Oncolytic virus CF33-hNIS (VAXINIA) is IMU’s lead candidate. CF33 and the MAST trial...
Read ArticleHighlights First patients dosed in higher dose cohorts, cohort 5 of intratumoral and intravenous...
Read ArticleHighlights As of 12 Jan, 38 patients have been dosed with CF33-hNIS virus under the Phase 1 VAXI...
Read ArticleHighlights IMU is focused on advancing four platform technologies , Allo CAR T cell Therapy, CF3...
Read ArticleMany of Australia's top brokers have been busy adjusting their financial models again, leading to t...
Read ArticleIt's been a tough year for Healius Ltd (ASX: HLS) shares. This ASX 200 healthcare stock has had an...
Read ArticleThe US Food and Drug Administration has stamped Imugene’s “Vaxinia” virus trials aimed at treating b...
Read ArticleHere’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 2...
Read ArticleThe ASX benchmark has ended Tuesday higher 8 of 11 sectors in the green Small caps led by Plenti G...
Read ArticleShares rebounded on Tuesday due to gains in real estate and gold, while the Australian dollar reache...
Read ArticleThe ASX200 has continued to gather early gains and is up nearly half a per cent – with every sector...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday. In afternoon trade, the benchmark...
Read ArticleI'm a firm believer in the philosophy that the best time to invest in ASX shares was probably yeste...
Read ArticleClinical-stage immuno-oncology company Imugene (ASX: IMU) has received fast-track designation from t...
Read Article28 Nov 2023 - A snapshot of the stocks on the move, featuring Namoi Cotton (ASX:NAM), Imugene (ASX:I...
Read ArticleRetail sales in October declined by 0.2% compared to September, falling short of the expected 0.1% i...
Read ArticleLink Administration Holdings Ltd (ASX: LNK) shares are catching the eye on Tuesday. In morning trad...
Read ArticleImugene (ASX:IMU) reaches a milestone in its MAST clinical program using its novel cancer-killing vi...
Read ArticleHighlights The US FDA awarded Fast Track designation to clinical program studying VAXINIA in bil...
Read ArticleNamoi Cotton (ASX:NAM) has received a non-binding, indicative and conditional offer (NBIO) from Lo...
Read ArticleThe Collins Foods Ltd (ASX: CKF) share price is having a strong session. In morning trade, the quic...
Read ArticleThe Pointsbet Holdings Ltd (ASX: PBH) share price is marching higher today. Shares in the All Ordin...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleThe Imugene Limited (ASX: IMU) share price is charging higher on Tuesday morning. At the time of wr...
Read ArticleASX futures were largely flat near 8:30 AEDT, up only 0.08 per cent (6pts). The ASX200 could go eith...
Read ArticleThe ASX offers some great opportunities for investors to build a reliable passive income stream. Ma...
Read ArticleFixed income ASX ETFs could be a good asset class to look at to invest in right now. If readers are...
Read ArticleThe Sayona Mining Ltd (ASX: SYA) share price is down 1.3% to 7.6 cents on Wednesday. It's a poor d...
Read ArticleThe Avita Medical Inc (ASX: AVH) share price is having a tough morning. At the time of writing, the...
Read ArticleASX lithium shares have been flogged to death as an investment theme the last few years, so are the...
Read ArticleThe Wildcat Resources Ltd (ASX: WC8) share price is trading at 81 cents on Friday, down 19.8% from...
Read ArticleThe Azure Minerals Ltd (ASX: AZS) share price is slightly higher on Friday amid a major shareholder...
Read ArticleMineral Resources Ltd (ASX: MIN) shares closed the session at $62.60 per share, down 0.32% amid the...
Read ArticleIt's a fact of investing life that there will always be another stock market crash. Market crashes...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleThe local share market Is tipped to make its greatest gains in over a month, with ASX futures sugges...
Read ArticleSayona Mining Ltd (ASX: SYA) shares have seen their fair share of ups and downs over the past three...
Read ArticleASX lithium share Mineral Resources Ltd (ASX: MIN) is trading at $60.30 per share, up 3.93% on Tues...
Read ArticleThe Avita Medical Inc (ASX: AVH) share price is having a banner day. Shares in the ASX healthcare s...
Read ArticleAt the start of each week, I like to look at ASIC's short position report to find out which share...
Read ArticleThis trading week seems to have gotten off to a shaky start so far this Monday. At the time of writ...
Read ArticleThis week’s Bulls N’ Bears profiled ASX runner is… Imugene. Its share price jumped more than 212 per...
Read ArticleHere’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 2...
Read ArticleASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US F...
Read ArticleThe ASX200 has finished the week, trading down just over half a per cent. All sectors lost ground...
Read ArticleThe ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant Small ca...
Read ArticleImugene has continued to set the ASX boards alight after revealing it had delivered the first dose o...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a disap...
Read ArticleAVITA jumps after providing bullish guidance Anatara up after holding AGM this morning Imugene dose...
Read ArticleThe Magnis Energy Technologies Ltd (ASX: MNS) share price is ending the week deep in the red. At on...
Read ArticleThe Imugene Limited (ASX: IMU) share price is continuing its incredible run and charging higher aga...
Read ArticleSydney-headquartered clinical stage immuno-oncology company Imugene (ASX: IMU) has achieved an early...
Read ArticleImugene (ASX:IMU) reaches a major milestone in its phase 1b clinical trial using azer-cel, dosing it...
Read ArticleWildcat Resources Ltd (ASX: WC8) shares are back from their trading halt on Friday and sinking into...
Read ArticleWildcat Resources (ASX:WC8) recently hit one-year returns of 2721 per cent In January of 2023, t...
Read ArticleWelcome to the end of the week. The ASX is set to trade red with ASX200 futures down 0.07 per cent (...
Read ArticleThe ASX has closed higher Healthcare leads sector gains Small caps led by KTA and FG1 The Aussi...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At t...
Read ArticleThe Wildcat Resources Ltd (ASX: WC8) share price won't be going anywhere on Thursday. That's becaus...
Read ArticleThe Imugene Limited (ASX: IMU) share price is rising again on Wednesday. At one stage today, the AS...
Read ArticleThe Australian dollar and bond yields slid after the Reserve Bank of Australia lifted the cash rate...
Read ArticleIt was only on Tuesday that we got the latest look at ASX 200 bank share Westpac Banking Corp (ASX:...
Read ArticleShortly before Without A Fight crossed the finish line to win the 2023 Melbourne Cup, the Reserve Ba...
Read ArticleThe Westpac Banking Corp (ASX: WBC) share price is having a poor session on Tuesday. In afternoon t...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is under pressure ahead of the Reserve Bank's meeting. In af...
Read ArticleOn Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a small gain. The benchmark...
Read ArticleWarren Buffett is called the Oracle of Omaha for good reason. Atop his phenomenal investing success...
Read ArticleOwners of Westpac Banking Corp (ASX: WBC) shares will soon be getting their FY23 final dividend pay...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has started the week positively. In afternoon trade, the ben...
Read ArticleHighlights To date, 34 heavily treated patients administered with CF33-hNIS All treatments have...
Read ArticleImugene has recorded positive early signals from the first phase of its metastatic advanced solid tu...
Read ArticleA Phase 1 metastatic advanced solid tumours (MAST) trial evaluating the safety and efficacy of novel...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is soaring higher today. Shares in the ASX biotechnology co...
Read ArticlePYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metasta...
Read ArticleThe Whispir Ltd (ASX: WSP) share price is shooting the lights out on Monday. The ASX tech share clo...
Read ArticleImugene has taken a further leap forward in its mission to track down and kill cancer tumours by adv...
Read ArticleImugene has taken a further leap forward in its mission to track down and kill cancer tumours by adv...
Read ArticleHighlights Phase 1 MAST trial has cleared cohort 4 of the IV arm of the monotherapy and IV cohor...
Read ArticleImugene (ASX:IMU) reaches the next cohort in the IV arm of its monotherapy dose escalation study, an...
Read ArticleClinical-stage immuno-oncology company Imugene (ASX: IMU) has announced that its Phase 1 MAS...
Read ArticleASX-listed medtech Imugene has dosed the first patient with its novel immunotherapy drug candidate “...
Read ArticleAlthea’s cannabis oil approved for reimbursement in Ireland Imugene dosed first patient in onCARlyt...
Read ArticleImugene (ASX:IMU) has announced that its CD19 oncolytic virotherapy drug candidate, onCARlyt...
Read ArticleImugene is poised to secure further development opportunities for its “super-charged” cell immunothe...
Read ArticleImugene (ASX:IMU) announces that its B cell immunotherapy, HER-Vaxx, and CF33 oncolytic virotherapy...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleThe US FDA has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer treatme...
Read ArticleThe US Food and Drug Administration (FDA) has transferred an investigational new drug (IND) applicat...
Read ArticleWorld Overnight SPI Overnight 7055.00 – 13.00 – 0.18% S&P ASX 200 7030.30 – 7.90 – 0.11%...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday. In afternoon trade, the benchmark...
Read ArticleIt hasn't been a great day for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares so far this...
Read ArticleAnother day, another set of 52-week highs for ASX uranium shares! Most uranium miners are rising o...
Read ArticleIt's been a pretty awful start to this Tuesday's trading for the S&P/ASX 300 Index (ASX: XKO) a...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has delighted...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is out of form on Monday. In afternoon trade, the benchmark...
Read ArticleCancer fighter Imugene has positioned itself as one of the most cashed-up med-techs on the ASX after...
Read ArticleThe TechnologyOne Ltd (ASX: TNE) share price is starting the week strongly. At the time of writing,...
Read ArticleClinical stage immuno-oncology company Imugene (ASX: IMU) has raised $18.2 million from a share purc...
Read ArticleWorld Overnight SPI Overnight 7186.00 – 14.00 – 0.19% S&P ASX 200 7196.60 – 33.80 – 0.47%...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleThe ASX 200 benchmark falls 0.5% as central bank boogeymen spook investors Energy pretty much on i...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) had another shaky day...
Read ArticleClinical-stage immuno-oncology company Imugene has secured new Japan Patent Office protection for it...
Read ArticleClinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a new patent by the Japan...
Read ArticleHighlights Imugene’s first-in-class programmed death-1 (PD1) vaccine, PD1-Vaxx has been granted...
Read ArticleImugene Limited (ASX: IMU) stock is in great demand with investors on Tuesday. In morning trade, th...
Read ArticleClinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the grant of a new pa...
Read ArticleFutures point to the ASX opening modestly higher, bolstered by gains on Wall Street overnight. Ov...
Read ArticleCancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on it...
Read ArticleCancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on it...
Read ArticleLumos granted approvals by the US FDA for the ViraDx test Imugene receives positive feedback from F...
Read ArticleImugene (ASX: IMU) has announced positive feedback from the US Food and Drug Administration (FDA) on...
Read ArticleASX futures were predicting the ASX will open slightly in the green to start the week in pre-morning...
Read ArticleIt ended up being a pretty lousy Tuesday for the S&P/ASX 200...
Read ArticleImugene (IMU) announces the clearance of the first cohort in its phase one MAST trial The trial i...
Read ArticleImugene has revealed that the phase-one trial of its anti-cancer virus “Vaxinia”, which is administe...
Read ArticleSydney-headquartered clinical stage immuno-oncology specialist Imugene (ASX: IMU) continues to build...
Read ArticleItâs that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&...
Read ArticleFutures indicate the ASX200 will open slightly higher as a new trading week commences, driven by gro...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleClinical stage immuno-oncology specialist Imugene (ASX: IMU) has added another key appointment to it...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has recorded yet another gai...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleWe’ve just had another mighty fine day for the S&P/ASX 200 Ind...
Read ArticleAt the start of each week, I like to look at ASICâs short position report to find out which sha...
Read ArticleNeuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year Eye...
Read ArticleWith so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The...
Read ArticleFresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is...
Read ArticleTelstra Group Ltd (ASX: TLS) shares and Vanguard Australian Shares High Yield ETF (ASX: VHY) are bo...
Read ArticleBy Greg Peel Choosing to Follow On It was a rock’n’roll session on the ASX200 on Friday, ahead of a...
Read ArticleThe pre-eminent benchmark of the Australian share market, the S&P/ASX 200 Index (ASX: XJO), nar...
Read ArticleThe ASX200 had a stronger session than expected, closing up, but only just. The real estate secto...
Read ArticleASX 200 benchmark falls, gains and wanes its way to just 0.03% for the day. Real Estate, resources...
Read ArticleIt has been another busy week for Australiaâs top brokers. This has led to the release of a large...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain on Friday. In afternoon...
Read ArticleThe ASX200 has gone against expectations and lifted ever so slightly by 0.1 of a per cent mid-sessio...
Read ArticleBuilding a portfolio of ASX shares that will pay you a generous income stream is a hard task. After...
Read ArticleThe Abacus Property Group (ASX: ABG) share price is ending the week on a high. In morning trade, th...
Read ArticleSydney-headquartered Imugene (ASX: IMU) has made a strong start to a $65 million capital raising aim...
Read ArticleStockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleImugene (IMU) receives firm commitments to raise $35 million through a share placement and will init...
Read ArticleThe Imugene Limited (ASX: IMU) share price has returned from its trading halt and dropped deep into...
Read ArticleAustralian company Imugene (ASX:IMU) has agreed with US-based Precision Biosciences to acqui...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleAfter a steep early drop, the benchmark stabilised to close 1.5% down. InfoTech and Materials fared...
Read ArticleOn Wednesday, the ASX experienced a significant drop in response to a global sell-off that took plac...
Read ArticleImugene (IMU) enters an agreement with Precision Biosciences to acquire an exclusive worldwide licen...
Read ArticleWe’re smack bang in the middle of ASX earnings season right now. And with earnings comes new divide...
Read ArticleAML3D (ASX:AL3) has received a $2M order from US Navy for submarine parts. In response, interim CE...
Read ArticleChina's shift towards deflation is causing concern in financial markets, yet some money managers sug...
Read ArticleClinical-stage immuno-oncology company Imugene (ASX: IMU) has entered into an agreement with US-base...
Read ArticleClinical-stage immuno-oncology company Imugene (ASX: IMU) has entered into an agreement with US-base...
Read ArticleThe money will be used to fund the acquisition of a license for Precision Biosciences’ azer-cel allo...
Read ArticleFutures are predicting that the ASX will open lower this morning, following losses across Europe and...
Read Article16 Aug 2023 - A snapshot of the stocks on the move, featuring AML3D (ASX:AL3), Imugene (ASX:IMU) and...
Read ArticleThe ASX200 closed the day 0.86 per cent lower with almost all sectors in the red except communicatio...
Read ArticleIt was a depressing start to the trading week for the S&P/ASX 200 Index (A...
Read ArticleWith so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The...
Read ArticleA little-known ASX All Ords share is setting the bar high today. In afternoon trade on Monday, the...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a dis...
Read ArticleImugene (IMU) VAXINIA trial is moving ahead to cohort four The company is effectively de-risking...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is leaping higher today. Shares in the S&P/ASX 200 Index...
Read ArticleAnteris Tech’s DurAVR THV was implanted successfully in a procedure Imugene moves forward to cohort...
Read ArticleClinical stage immuno-oncology company Imugene (ASX: IMU) has announced that a Phase 1 MAST (metasta...
Read ArticleHighlights Imugene’s VAXINIA MAST trial has cleared cohort 3 IT monotherapy dose escalation stud...
Read ArticleThe Carsales.Com Ltd (ASX: CAR) share price is on the move on Monday. At the time of writing, the a...
Read ArticleFutures suggest the ASX will open in the red this morning, ahead of fresh ABS wage data, which will...
Read ArticleThe Renascor Resources Ltd (ASX: RNU) share price is down 3.6% today despite another positive updat...
Read ArticleThe Renascor Resources Ltd (ASX: RNU) share price is down 21% over the past two days following an u...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleFutures suggest the ASX will open lower today as investors contemplate the unexpected downgrade of t...
Read ArticleWhilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of N...
Read ArticleLOS ALTOS, CA, USA, July 20, 2023/EINPresswire.com/ -- RenovoRx and Imugene Announce Collaboration t...
Read ArticleImugene (IMU) enters a strategic research collaboration with RenovoRx to optimise the delivery of it...
Read ArticleHighlights Imugene has formed a partnership with clinical-stage biopharmaceutical firm – RenovoR...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage immuno-oncol...
Read ArticleWorld Overnight SPI Overnight 7286.00 + 2.00 0.03% S&P ASX 200 7323.70 + 39.90 0.55% S&a...
Read ArticleFinally, a positive day for the S&P/ASX 200 Index (ASX: XJO)! After falling in both Monday a...
Read ArticleThe Energy sector demonstrated strong growth, with a rally of 1.7%. Ampol (ASX:ALD) experienced a si...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncol...
Read ArticleImugene (IMU) receives US patent approval to protect its oncolytic virotherapy CF33, including VAXIN...
Read ArticleWoodside Energy (ASX:WPL), reported a 29% decline in revenue for the second quarter, amounting to $U...
Read ArticleHighlights Imugene has secured a patent for its licenced oncolytic virotherapy in the United Sta...
Read ArticleThe Peninsula Energy Ltd (ASX: PEN) share price is having a day to forget on Wednesday. At one stag...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is leaping higher today, up 7.5% at the time of writing. Sha...
Read ArticleImpediMed (ASX:IPD) are the first top 5 national payor covering SOZO testing for cancer patients a...
Read ArticleThe BetaShares Australian Dividend Harvester Fund (ASX: HVST) is one of the more popular high-yield...
Read ArticleHighlights Imugene has appointed Dr Ron Weitzman as its interim CMO. Dr Weitzman has an experie...
Read Article19 Jul 2023 - A snapshot of the stocks on the move, featuring ImpediMed (ASX:IPD), Imugene Limited (...
Read ArticleTim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics. By Tim Bore...
Read ArticleThe fund manager L1 Capital has identified two S&P/ASX 200 Index (ASX: XJO) shares that could b...
Read ArticleThe ASX 200 is down nearly 0.5 per cent at market close, declining throughout the day after a strong...
Read ArticleThis content is created by Smallcaps Authors. [Author : Colin Hay] Clinical stage immuno-oncology...
Read ArticleImugene (IMU) to proceed with a fourth dose cohort in the phase one trial of its oncolytic virothera...
Read ArticleHighlights Phase I clinical trial of CHECKvacc is set to proceed to the fourth dose cohort. The...
Read ArticleThe Vulcan Energy Resources Ltd (ASX: VUL) share price is pushing higher again on Tuesday. In after...
Read ArticleIt’s been a bumpy but overall positive end for the S&P/ASX 200 Index (ASX: XJO) for this Fri...
Read ArticleASX value shares and growth shares both went up in FY23, but value stocks did a bit better. The S&...
Read ArticleIt’s the last day of the financial year and significant changes are set to take place from tomorrow....
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on course to finish the week with a small decline. At the...
Read ArticleHighlights Imugene’s new and significant HER-Vaxx data has been presented at the World Congress...
Read ArticleImugene (IMU) presents “new and significant” HER-Vaxx data at the World Congress of Gastrointestinal...
Read ArticleASX set to open lower this morning after a slow day on Wall Street overnight. ASX 200 Futures Index...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncol...
Read ArticleThere were 432,000 job vacancies in May 2023 – 9,000 less than in February. The Australian Bureau...
Read ArticleImugene (IMU) receives an extension of its PD1-Vaxx patent from the United States Patent Office unti...
Read ArticleHighlights The United States Patent Office has awarded a patent to the company’s immunotherapeut...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncol...
Read ArticleWhat a day for the S&P/ASX 200 Index (ASX: XJO) we had this Wednesday. After yesterday’s more...
Read ArticleThe ASX jumps 1.1pc on better-than-expected inflation figures. Australia’s rate of inflation pull...
Read ArticleThe All Ordinaries Index (ASX: XAO) is up a healthy 1.09% in afternoon trade, boosted by todayâs...
Read ArticleThe Nickel Industries Ltd (ASX: NIC) share price is pushing higher on Wednesday morning. At the tim...
Read ArticleWilsons equity strategist Rob Crookston is a happy man. Despite the turbulence in the general marke...
Read ArticleThe Imugene Limited (ASX: IMU) share price has continued downward in the last 12 months, with the c...
Read ArticleArgosy Minerals Limited (ASX: AGY) shares have been having a tough time in 2023. Since the start of...
Read ArticleHighlights IMU has welcomed Ms Kim Drapkin, a prominent US biotech executive, as Non-Executive D...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a strong gain. At the time...
Read ArticleThere were some defining moments for scores of ASX shares over the week gone by. Here are five stoc...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) traded in the green on Friday, closing the week 0.32% higher a...
Read ArticleImugene says it is ready to advance to the phase of testing for its cancer-killing virus, the VAXINA...
Read ArticleThe market is tracking higher in midday trade, up nearly 0.5 per cent. Economists from the Common...
Read ArticleIt’s looking like the S&P/ASX 200 Index (ASX: XJO) is heading for a positive end to the trading...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positi...
Read ArticleItâs a bright day on the bourse, with the All Ordinaries Index (ASX: XAO) lifting 0.37% at the ti...
Read ArticleImugene’s (IMU) phase one metastatic advanced solid tumours (MAST) trial evaluating its novel cancer...
Read ArticleAnteris’ study is progressing well at the one year and 30-day time points Imugene’s Phase 1 trial h...
Read ArticleThis content is created by Smallcaps Authors. [Author : Colin Hay] Advanced immuno-oncology specia...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) finished the week in the green, gaining 0.48% on Friday to clo...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleASX 200 lithium shares fell against the benchmark S&P/ASX 200 Index (ASX: XJO) today. Lithium...
Read ArticleThe ASX 200 finished the day higher, up 0.2 per cent at 7,110.8 points, after the United States’ hou...
Read ArticleA new month is here, so what better time to look at some new additions to your portfolio? If youâ...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At t...
Read ArticleParadigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-ba...
Read ArticleHighlights IMU, an Australian immuno-oncology company, has dosed first patient in the combinatio...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncol...
Read ArticleImugene (ASX:IMU) has announced that the first patient has been dosed in the combination coh...
Read ArticleAfter starting the day off on the wrong foot, the S&P/ASX 200 Index (ASX: XJO) tumbled even fur...
Read ArticleThe market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts...
Read ArticleASX rare earths share Arafura Rare Earths Ltd (ASX: ARU) has plummeted in the last three months. T...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) ended the week in the green, gaining 0.59% on Friday to close...
Read ArticleFor the final day of the trading week, the ASX was up more than 0.5 per cent. Ship building compa...
Read ArticleThis content is created by Smallcaps Authors. [Author : Filip Karinja] Cancer immunotherapy house...
Read ArticleImmutep gets US FDA clearance to start Phase 1 study Noxopharm says its Sofra platform is effective...
Read ArticleImugene (IMU) receives US Food and Drug Administration (FDA) Investigational New Drug (IND) clearanc...
Read ArticleThe ASX is expected to open slightly higher on Friday as reports suggest the US debt ceiling talks c...
Read ArticleHighlights Combination of IMU’s onCARlytics and Eureka Therapeutics' ARTEMIS® cell receptor plat...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncol...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) shook off early losses on Friday to close the final session of...
Read ArticleS&P/ASX 200 Index (ASX: XJO) lithium share Pilbara Minerals Ltd (ASX: PLS) is rocketing amid ne...
Read ArticleEngineering companies are not often discussed among ASX investors, but there are a couple at the mo...
Read ArticleEven though lithium prices have cooled off over recent months, battery ingredients such as that and...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) slipped into the red on Tuesday, closing todayâs session 0.1...
Read ArticleAh, Budget Day. Itâs pretty much Christmas for those of us who are both finance and politics nerd...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) seems to have taken a turn for the worse today. After yesterda...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday. In afternoon trade,...
Read ArticleS&P/ASX 200 (ASX: XJO) stocks are down 0.3% at lunchtime on Tuesday, but as always, there are o...
Read ArticleThis content is created by Smallcaps Authors. [Author : Lorna Nicholas] Imugene (ASX: IMU) has unv...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleThe Imugene Limited (ASX: IMU) share price lifted 4% today after the company released its March qua...
Read ArticleToday marked the penultimate day of March quarterly reports, and it appears to have pushed the mater...
Read ArticleImugene’s (IMU) spent the March quarter continuing the development of its cancer-killing virus, VAXI...
Read ArticleAmid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught...
Read ArticleThis content is created by Smallcaps Authors. [Author : Lorna Nicholas] Imugene is developing immu...
Read ArticleHighlights Imugene has received its R&D tax refund of nearly AU$12.6 million for FY22. The...
Read ArticleImugene (IMU) presents positive imaging data from its viral drug oncolytic virotherapy candidate, CH...
Read ArticleThis content is created by Smallcaps Authors. [Author : Lorna Nicholas] Clinical stage immune-onco...
Read ArticleHighlights Imugene has presented positive imaging data on its oncolytic virotherapy candidate, C...
Read ArticleLocal share will open flattish, tracking movements in New York Tesla’s profit margins plunge after...
Read ArticleThis ASX rare earths stock is exploding on the market today amid new drilling results. Larvotto Re...
Read ArticleWhen it comes to ASX lithium stocks, Nova Minerals Ltd (ASX: NVA) is probably not a share that init...
Read ArticleMost index exchange-traded funds (ETFs) on the ASX work in a similar way. The fund tracks a single...
Read ArticleThe Imugene Ltd (ASX: IMU) share price has been racing ahead in the last month. Shares in the ASX...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) spent the day in the green on Monday, rising 0.27% to close at...
Read ArticleAfter wobbling in and out of the green this morning, the S&P/ASX 200 Index (ASX: XJO) cemented...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) traded in the red ahead of the Easter long weekend, falling 0....
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) put on a rocky performance on Wednesday, eventually closing th...
Read ArticleRed 5 (RED) has logged its strongest month of production to date. In March, more than 17,000 ounc...
Read ArticleThis content is created by Smallcaps Authors. [Author : Danica Cullinane] Clinical stage immune-on...
Read ArticleImugene (IMU) doses its first patients in the intravenous and intratumoral arms in cohort three of t...
Read ArticleHighlights Imugene has dosed first patients in the intravenous and intratumoral arms in cohort 3...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.78% in Fridayâs session t...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) slipped lower on Friday, falling 0.19% to close at 6,955.2 poi...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) recovered some of its Monday losses today, closing Tuesdayâs...
Read ArticleShareCafeBig gains from Tech push ASX 0.86% higher by Peter Milios The Australian stock market exp...
Read ArticleThe share market surged to a two-week high after the Reserve Bank softened its interest rates guidan...
Read ArticleAussie shares hovered near a two-week high in cautious trade ahead of this afternoon’s RBA interest...
Read ArticleThis content is created by Smallcaps Authors. [Author : Danica Cullinane] Immuno-oncology company...
Read ArticleCancer cure researcher Imugene has announced that the first patients for its Phase 1 vaxinia combina...
Read ArticleImugene (IMU) doses the first patients in a combination study to test its cancer-killing virus, VAXI...
Read ArticleHighlights Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) ended the week in the red, falling 0.86% on Friday to close at...
Read ArticleThe Treasury Wine Estates Ltd (ASX: TWE) share price is on the slide on Wednesday morning. At the t...
Read ArticleThe Appen Ltd (ASX: APX) share price has been in a bit of a sorry state for a while now. Appen shar...
Read ArticleShareCafeEnergy’s efforts are not enough to lift the ASX by Peter Milios The ASX 200 index fell by...
Read ArticleASX artificial intelligence (AI) stocks havenât had a great run over the past 12 months. To say t...
Read ArticleThe Appen Ltd (ASX: APX) share price is taking a tumble, down 9.9% in Monday morning trade. The art...
Read ArticleThe Endeavour Group Ltd (ASX: EDV) share price is charging ahead after the company dropped its earn...
Read ArticleThere are plenty of blue chip ASX 200 shares to choose from on the Australian share market. But thr...
Read ArticleOn Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a disappointing note. The ben...
Read ArticleShareCafeASX closes 0.8% lower as UBS lift their cash rate peak forecast by Peter Milios UBS Chief...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) ended the week just the way it started it â in the red. The...
Read ArticleReporting from Sydney this morning, clinical-stage cancer immunotherapy developer Imugene [ASX:IMU]...
Read ArticleThe share market’s sparkling start to the year lost some of its fizz as the threat of higher interes...
Read ArticleShares fall to a three-week low amid RBA's 'hawkish' update. CBA says rate cut needed by end of year...
Read ArticleThe share market slumped to a two-and-a-half week low as financial markets continued to adjust their...
Read ArticleShareCafeASX down at noon despite RBA comments that inflation has likely peaked by Peter Milios Th...
Read ArticleShareCafeStocks of the Hour: CZL, RGL, ALA Consolidated Zinc (ASX:CZL) has...
Read ArticleHighlights Imugene Limited has secured a Notice of Allowance relating a US patent application fo...
Read ArticleThe share price of S&P/ASX 200 Index (ASX: XJO) biopharmaceutical developer Imugene Limited (AS...
Read ArticleImugene (IMU) receives a Notice of Allowance from the US Patent and Trademark Office for its PD1-Vax...
Read ArticleThe ASX will open lower on Friday after a Wall Street slump overnight Disney and Yahoo to lay off t...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) posted its first gain of the week on Wednesday, lifting 0.35%...
Read ArticleShareCafeASX closes 0.13% higher as Bitcoin spikes and China lifts coal ban by Peter Milios At the...
Read ArticleShareCafeASX up 0.58% at noon after Fed comments of decreasing inflation by Peter Milios The ASX h...
Read ArticleImugene (IMU) advances its phase one metastatic advanced solid tumours study The phase one trial...
Read ArticleHighlights Imugene Limited’s Phase 1 MAST study has cleared cohort 2 of both the intravenous (IV...
Read Article02 Feb 2023 - A snapshot of the stocks on the move featuring Splitit (ASX:SPT), European Metals Hold...
Read ArticleShareCafeStocks of the Hour: SPT, EMH, IMU, ALY Buy Now Pay Later platform,...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleHighlights A new 100-day high for ASX 200 was noted at market close on 1 February 2023. The ASX...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) shot to a nine-month high of 7,537.7 points today. However, by...
Read ArticleThe share market cruised to a fresh nine-month high after Wall Street rallied into tonight’s interes...
Read ArticleThe share market recovery of 2023 got back on track as a first rise in three sessions lifted the S&a...
Read ArticleShareCafeAus shares close 0.07% lower but rise 6.2% in January by Peter Milios Australian shares f...
Read ArticleShareCafeHigh cost of living causes a fall in retail sales: ASX up 0.22% at noon by Peter Milios R...
Read ArticleImugene (IMU) has taken another step forward in its efforts to treat and eradicate tumours in cancer...
Read ArticleThe ASX ended Friday flattish, but is at a 9-month high Energy and Miners led today after a series...
Read ArticleThe share market rose to a fresh nine-month high as strength in resource stocks helped offset weak l...
Read ArticleHighlights Imugene Limited’s HER-Vaxx and CF33 technologies being presented at the ASCO Gastroin...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) soared to its highest point in nine months on Thursday, peakin...
Read ArticleThe ASX closed flat on Wednesday Local investors are closely watching earnings reports in both the...
Read ArticleThe ASX finally snapped after a 4-day winning streak China’s GDP grew more than expected Miners wer...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) kicked off the week strong, leaping 0.82% on Monday to close a...
Read ArticleOptimism about China reopening and hopes for a slowdown in interest rate hikes fuelled the share mar...
Read ArticleThe ASX has had a big first two weeks, rising by over 4% Investors are bullish as inflation looks t...
Read ArticleA seventh rise in eight sessions powered the share market to its highest in more than a month after...
Read ArticleThere was likely a spring in the step of S&P/ASX 200 Index (ASX: XJO) investors today as the ma...
Read ArticleThe ASX surged by another 1% on Thursday The all crucial US CPI will be released later today (US ti...
Read ArticleRecord retail sales helped the share market brush off the prospect of further interest rate hikes th...
Read ArticleThe ASX down by 0.30% on Tuesday Iron ore miners pare gains as China clamps down on speculation Jer...
Read ArticleShareCafeAlmost all sectors lower despite signs of optimism in the US: ASX down 0.3% at noon by Pete...
Read ArticleMarket goes out too hard, too early and beds down for a lengthy afternoon snooze Tempus Resources s...
Read ArticleThe ASX rose in a broad brushed rally Fortescue’s CFO of 13 years quit Australian and US CPI will b...
Read ArticleThe share market sealed its longest win run since early November with a fourth straight rise followi...
Read ArticleHighlights Imugene Limited (ASX:IMU) marked 2022 with breakthrough developments in its clinical...
Read ArticleImugene has now crossed ethics approval off is list, and the way is now clear for clinical trials to...
Read ArticleAussie shares hit a three-week high amid optimism about cooling inflation and China reopening. Th...
Read ArticleLBT Innovati0ns engaged by global pharma company, AstraZeneca Volpara nabs $7m plus contracts Imuge...
Read ArticleHighlights Imugene Limited (ASX:IMU) has received human research ethics approval for Phase I hum...
Read ArticleImugene (IMU) receives Human Research Ethics Committee (HREC) approval to commence a phase one clini...
Read ArticleMiners lead shares higher; IGO-Tiangi to buy Essential Metals; Ian Wells to leave Fortescue; Core Li...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) wobbled in and out of the green this afternoon before ultimate...
Read ArticleAn early rally lost momentum following soft Chinese economic data and as negative US futures suggest...
Read ArticleAustralian stocks climbed to their highest in a week after Wall Street took in its stride confirmati...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) recovered from Tuesdayâs fall today, lifting 1.63% to close...
Read ArticleAussie shares climbed into positive territory for 2023 after reports of fresh support for China’s ai...
Read ArticleThe share market bounced off an eight-week low after Wall Street pared sharp initial losses during t...
Read ArticleEnding the year on a high note, the S&P/ASX 200 Index (ASX: XJO) rallied on the last trading da...
Read ArticleHighlights The ASX 200 benchmark index closed in the green today (December 30), gaining 34.80 po...
Read ArticleAussie shares fell for a third session, pacing broad falls on Wall Street as markets priced in the r...
Read ArticleA whopping insider buy just went down with shares in technology-focused listed investment company (...
Read ArticleIt can take a long time to bring a new drug to market, but companies that succeed reap mighty reward...
Read ArticleThe S&P/ASX 200 falls on first day of Christmas trading week, down 0.21% Nickel Industries (ASX...
Read ArticleHighlights The ASX 200 benchmark index closed in the red today (December 19), losing 14.70 point...
Read ArticleAustralian shares tracked falls on Wall Street after the Federal Reserve raised US interest rates an...
Read ArticleLocal shares finished higher ahead of the Fed rates call tonight Energy and gold stocks led Binance...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) traded in the green on Tuesday, recovering some of yesterdayâ...
Read ArticleThe share market rose for only the second time in six sessions before halving its gains ahead of ris...
Read ArticleLocal shares finished slightly higher ahead of the FOMC meeting later tonight Sam Bankman-Fried arr...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) had another shocker today, notching up its third loss in a row...
Read ArticleEnergy stocks dragged ASX lower Core Lithium got a Sell rating from Goldman Sachs RBA says it’s sti...
Read ArticleIn morning trade, the Santos Ltd (ASX: STO) share price is edging lower. At the time of writing, th...
Read ArticleOn Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a gain. The benchmark index...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) got off to a good start this week. The index finished Mondayâ...
Read ArticleThe BHP Group Ltd (ASX: BHP) share price has charged higher today. BHP shares are up 2.80% near...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a so...
Read ArticleNSB files new patent in Australia Imugene doses first patient in Phase 1 trial Cronos and MGC Pharm...
Read ArticleHighlights Australian shares opened flat on Wednesday. The ASX 200 rose marginally in ope...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) spent the afternoon in the green on Tuesday. The index closed...
Read ArticleThe ASX snapped a 4-day winning streak Energy stocks paced the bourse lower The RBA apologised over...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleThe Imugene Limited (ASX: IMU) share price has had a tough run lately. Imugene shares have dropped...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwise...
Read ArticleShareCafeEnergy rallies on optimism surrounding China’s Zero-COVID policy: ASX closes 0.27% lower by...
Read ArticleHighlights The ASX 200 benchmark index closed in the red today (November 16), losing 19.40 point...
Read ArticleThe ASX 200 retreated on Wednesday IMF says the RBA needs to keep hiking rates Trump announced his...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) slipped on Tuesday as lithium stocks weighed on the market. Th...
Read ArticleShareCafeASX falls after lithium stocks crumble: ASX closes 0.07% lower by Peter Milios Sectors we...
Read ArticleLithium stocks dragged down the ASX today Cannon-Brookes wins AGL board tussle at the AGM CBA repor...
Read ArticleImugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of the Soc...
Read ArticleThe ASX dropped 0.5% on Thursday Origin Energy gets takeover offer, shares up 35% Key US inflation...
Read ArticleThe ASX up 0.53% with 8 out of 11 sectors in the green Low Aussie dollar is lifting petrol prices w...
Read ArticleArovella Therapeutics (ALA) is set to receive a European patent for its iNKT cell therapy platform,...
Read ArticleThe ASX up 0.54% with 6 out of 11 sectors in the green RBA raises forecasts for inflation, again, e...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) finished the week on a strong note. It gained 0.5% on Friday t...
Read ArticleThe ASX 200 sank almost 2% on Thursday following the Fed’s 75bp hike last night All sectors except...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) spent a third consecutive day in the green on Wednesday. The i...
Read ArticleHighlights The ASX 200 benchmark index closed up today (1 November), gaining 113.40 points or 1....
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) gained on Tuesday as the Reserve Bank of Australia (RBA) hiked...
Read ArticleThe share market hit its highest in seven weeks after the Reserve Bank lifted benchmark interest rat...
Read ArticleThe ASX rose another 1% on Tuesday The RBA hiked its cash rate by 25bp, in line with expectations G...
Read ArticleThe ASX 200 rose for the sixth time in seven sessions ahead of a likely interest rate rise this afte...
Read ArticleShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter...
Read ArticleShareCafeStrong finish despite tomorrow’s expected rate hike: ASX closes 1.15% higher by Peter Milio...
Read ArticleThe ASX 200 finished 1% higher on Monday Australian retail sales rose again in September Graincorp...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) recovered from Fridayâs 0.87% fall, and then some, today. Th...
Read ArticleThe share market surged to its highest close in almost seven weeks as positive US leads and hopes fo...
Read ArticleOn the raw numbers, shareholders of Qantas Airways Limited (ASX: QAN) should be a happy lot. Qantas...
Read ArticleThe Sayona Mining Ltd (ASX: SYA) share price is up 2.13% this afternoon amid positive price movemen...
Read ArticleTPG Telecom Limited (ASX: TPG) shares are in the green today amid a strategic update. The telecomm...
Read ArticleAustralian shares rallied for the fifth time in six sessions as the prospect of the Dow’s best month...
Read ArticleShareCafeIT sector rallies to lift the market: ASX up 0.94% at noon The local market has commenced t...
Read ArticleNuheara secures FDA over-the-counter approval for its new affordable hearing aid Nitro Software rej...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is soaring higher on the market today. After surging 6% hig...
Read ArticleThe Liontown Resources Limited (ASX: LTR) share price is up 2.69% in lunchtime trading amid the com...
Read ArticleImugene (IMU) begins dosing the second cohort in its phase one study of its cancer-killing virus, VA...
Read ArticleItâs been a good year so far for those invested in S&P/ASX 200 Index (ASX: XJO) coal share Co...
Read ArticleCommonwealth Bank of Australia (ASX: CBA) shares are in the green again today, after finishing in p...
Read ArticleHighlights Australian shares opened flat on Monday. The ASX 200 rose marginally in openin...
Read ArticleThe ASX tumbled by almost 1% on Friday, trimming its gains to less than 2% for the week Elon Musk f...
Read ArticleHighlights The S&P/ASX 200 closed lower on Friday (28 October 2022), dropping 61.80 points o...
Read ArticleAussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering so...
Read ArticleThe ASX is up 0.50% with Energy leading the way Energy stocks gain as coal plays led again The Euro...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) spent a fourth consecutive day in the green on Thursday. The i...
Read ArticleNeurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closi...
Read ArticleThe ASX 200 tracked Wall St higher RBA says it wants households to reduce spending to curb inflatio...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleIn this week's Weekly Insights:-Investing In Non-Profitable Companies-Corporate Updates: Early Signa...
Read ArticleThe ASX closed higher on Wednesday Corporate earnings were the focus as BHP, Origin Energy and Beac...
Read ArticleASX regains yesterday’s losses as volatility in the market continues All ASX sectors rose except En...
Read ArticleASX healthcare shares have been a mixed bag in 2022. The industry was flourishing during the later...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) closed in the red after spending most of today in the green. T...
Read ArticleThe ASX finished flat on Wednesday, with Financial and Real Estate leading the way Iron ore miners...
Read ArticleShareCafeASX continues its woes: Aus shares close 0.34% lower by Peter Milios The ASX kept sliding...
Read ArticleHighlights The ASX 200 benchmark index closed down today (11 October), losing 0.34% to end at 6,...
Read ArticleThe ASX is down 0.24% with 6 out of 11 sectors in the red 290 Aussie listed companies are expected...
Read ArticleA share market rebound ran out of gas as a global bond market sell-off accelerated, pressuring US eq...
Read ArticleGains in mining and industrial stocks helped the ASX pare two days of falls despite a fourth straigh...
Read ArticleThe share market started the week with a sharp loss as investors booked profits from last week’s ral...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) broke a three-day winning streak on Friday. The index dumped 0...
Read ArticleThe ASX drops 0.80% with 10 out of 11 sectors in the red Australia outperforms US and UK markets ye...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleThe Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial update...
Read ArticleShareCafeArovella Therapeutics (ASX:ALA) partners with Imugene (ASX:IMU) Arovella Therapeutics Li...
Read ArticleShareCafeASX erases yesterday’s gains: Aus shares close 0.5% lower by Lauren Hayes It was choppy t...
Read ArticleThe ASX was down 0.55% on Wednesday AUD drops below US64c RBA tells the ASX to improve its governan...
Read ArticleThe Zip Co Ltd (ASX: ZIP) share price is down 0.44% today to 68 cents. What a shocker this company...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) traded in the green on Tuesday following yesterday’s rough sta...
Read ArticleThe ASX 200 bounced back modestly on Tuesday Mining and Energy stocks led the bounce The Pound Ster...
Read ArticleThe Newcrest Mining Limited (ASX: NCM) share price has had a really tough time in 2022. Over the la...
Read ArticleShareCafeEvening Report: 26 September, 2022 by Paul Sanger Australian shares have started the week...
Read ArticleBenchmark set to end the day down 1.5% Small caps smashed down 4.2% Greenwing up 70% on Chinese inv...
Read ArticleThe ASX has extended its losses on Monday on risk-off sentiment Energy and Mining led the losses Tw...
Read ArticleShareCafeLunch Report: 26 September, 2022 by Paul Sanger Australian shares have started the week s...
Read ArticleShareCafeStocks of the Hour: 26 September, 2022 Arovella Therapeutics (ASX:...
Read ArticleThe Zip Co Ltd (ASX: ZIP) share price is avoiding the worst of a brutal sell-off today. Though, the...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleThe Link Administration Holdings Ltd (ASX: LNK) share price is falling again on Monday. In early tr...
Read ArticleArovella Therapeutics (ALA) partners with Imugene (IMU) to conduct a pre-clinical trial to target so...
Read ArticleOne of my worst performers in my ASX share portfolio this year has been Newcrest Mining Ltd (ASX: N...
Read ArticleOn Wednesday, the S&P/ASX 200 Index (ASX: XJO) was well and truly out of form and sank deep i...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) waved farewell to eight companies on Monday morning. The benc...
Read ArticleASX 200 down 1.6% Small caps short 1.3% Real Estate stocks hit ahead of FOMC meet The benchmark...
Read ArticleHighlights: The S&P/ASX 200 closed down on Wednesday (21 September 2022), losing 1.56% to 6,...
Read ArticleThe ASX 200 fell 1.60% to a 2-month low on Wednesday Gold miners, Tech and Real Estate were hit har...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is on course to end...
Read ArticleShareCafeLunch Report: 21 September, 2022 by Paul Sanger Australian shares have dropped in morning...
Read ArticleImugene (IMU) doses the first patient in the intravenous cohort of its VAXINIA phase one clinical tr...
Read ArticleTelix Pharma releases positive study results for TLX101 Imugene doses first patient in Phase 1 clin...
Read ArticleThe ASX closed 1.6 per cent lower to a two-month low amid jitters about the fallout of the next US r...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) rebounded from its recent suffering, driven higher by mining...
Read ArticleThe share market fell to a two-month low as investors braced for another jumbo US rate hike. The...
Read ArticleA holiday-shortened trading week got off to a downbeat start as gains in mining and property stocks...
Read ArticleImugene (IMU) receives the DIR licence required to expand its phase one clinical trial targeting pat...
Read ArticleThe Imugene Limited (ASX: IMU) share price is shooting higher on Monday morning. At the time of wri...
Read ArticleHighlights The Australian share market opened in the red. The ASX 200 fell 0.80 points, o...
Read ArticleThe Imugene Limited (ASX: IMU) share price finished flat for today, but has been in the red for wee...
Read ArticleOn Tuesday, cancer immunotherapy developer Imugene [ASX:IMU] announced an $80 million placement to f...
Read ArticleThe share market sealed its longest winning run in six weeks with a fourth day of gains amid expecta...
Read ArticleThe share market regained 7000 as its longest win run in more than a month entered a fourth day....
Read ArticleThe Imugene Limited (ASX: IMU) share price has come out of a trading halt today. This comes after t...
Read ArticleThe ASX is set for a positive session Wall Street stocks surged again overnight Asian markets to cl...
Read ArticleImugene (IMU) taps private investors for $80 million via a share placement to ensure a “long runway”...
Read ArticleHighlights The Australian share market opened higher on Tuesday. The ASX 200 rose 10.40 p...
Read ArticleClinical trials access startup HealthMatch has raised $10 million in Series C. The round was led by...
Read ArticleImugene (IMU) enters a trading halt ahead of a capital raise to facilitate investment from two new i...
Read ArticleASX 200 gains 1% Small Caps index does the same, but then gives it all back ODE wins and NIC MD Ju...
Read ArticleThe Imugene Limited (ASX: IMU) share price isnât going anywhere right now. The stock has been put...
Read ArticleHighlights The ASX 200 benchmark index closed up today (September 9), gaining 0.66% to 6,894.20...
Read ArticleShareCafeLunch Report: 9 September, 2022 by Paul Sanger Australian shares are on track to end the...
Read ArticleThe Lithium Power International Ltd (ASX: LPI) share price is immobile today following the ASX’s d...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is trading well into the green in early afternoon trade on...
Read ArticleThe ResApp Health Ltd (ASX: RAP) share price is in the green today as investors digest the latest n...
Read ArticleThere’s a new development in the fight against the Zika virus. Invion (ASX:IVX) has just demonstrate...
Read ArticleImugene (IMU) doses the first patient in its nextHERIZON phase two clinical trialThe trial is invest...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the first patien...
Read ArticleHighlights The ASX 200 benchmark index closed up today (5 September), gaining 0.34% to end at 6,...
Read ArticleThe ASX finishes higher on Monday Energy / Resource only outperforming sectors ASX 200 quarterly r...
Read ArticleThe share market steadied on the eve of an increase in interest rates as a US market holiday and a r...
Read ArticleA rebound in resource stocks helped the share market weather weak overseas leads ahead of a likely r...
Read ArticleShareCafeLunch Report: 5 September, 2022 by Paul Sanger The ASX moved higher in Monday trading, de...
Read ArticleBiotechnology company Imugene (IMU) opens two additional cohorts for its phase one metastatic advanc...
Read ArticlePharmaxis gets ~$5m to collaborate on a Phase 2 study of lead drug, PXS‐4728. Imugene escalates to...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwise...
Read ArticleThe Imugene Limited (ASX: IMU) share price is in the red today despite a clinical trial update. I...
Read ArticleWorld Overnight SPI Overnight 6839.00 – 69.00 – 1.00% S&P ASX 200 6986.80 – 11.50 – 0.16%...
Read ArticleShareCafeEvening Report: 31 August, 2022 by Paul Sanger Australian shares were weaker today, dragg...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) put out a wobbly performance on Wednesday, opening and closin...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on mute after the ASX-listed biotech company reported...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) bounced back today following a 2% tumble that saw only four sh...
Read ArticleThe ASX 200 bounced back on Tuesday Woodside triples dividends All 11 sectors finish in the green...
Read ArticleThe stock market suffered its heaviest loss in two and a half months as investors reacted to rates j...
Read ArticleThe share market slumped to a three-and-a-half-week low after interest rate jitters triggered Wall S...
Read ArticleASX healthcare shares have been a mixed bag this earnings season, with some names completely blowin...
Read ArticleThe Appen Ltd (ASX: APX) share price took off in early trade on Thursday before tumbling into the r...
Read ArticleThe Appen Ltd (ASX: APX) share price is in focus after the machine learning and artificial intellig...
Read ArticleThe Imugene share price surged 20x to 71c before plunging to 25c in 2022 Here’s what the experts pr...
Read ArticleThe BrainChip Holdings Ltd (ASX: BRN) share price is in the green in early trading on Wednesday ami...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) shares in this article may not be thought of as leading ASX di...
Read ArticleWith ASX reporting season in full swing, S&P/ASX 200 Index (ASX: XJO) shares are declaring divi...
Read ArticleOn Tuesday, the S&P/ASX 200 Index (ASX: XJO) was out of form again and sank into the red. The...
Read ArticleThe Imugene Limited (ASX: IMU) share price finished the session on Tuesday at 25 cents — down 3.85%...
Read ArticleThe ASX 200 index fell by 1% on Tuesday Energy stocks rose as European’s benchmark for natural gas...
Read ArticleThe ASX 200 finished lower today Xero dragged down Tech sector Australia’s jobless rate is at 3.4%...
Read ArticleThe ASX 200 is up by 0.20% on Wednesday Australia’s wage increases by only 2.6% Earnings results do...
Read ArticleThe market may have been pushing higher again on Tuesday, but the same cannot be said for the Appen...
Read ArticleThe Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is plummeting after coming out of a tr...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe ASX 200 rose by 1% on Thursday The lithium sector caught a bid on the back off a report from Ch...
Read ArticleThe Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company...
Read ArticleHighlights The ASX 200 benchmark index ended in red today, losing 0.53% to end at 6,992.70 point...
Read ArticleHighlights The ASX 200 benchmark index ended in red today, losing 0.53% to end at 6,992.70 point...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) slumped on Wednesday, weighed down by tech shares. The index w...
Read ArticleAustralian shares fell for the first time in four sessions as a global market retreat continued ahea...
Read ArticleThe ASX 200 dips on Wednesday US CPI will be released later tonight Elon Musk offloads US$7bn of sh...
Read ArticleBiotech immunotherapy company Imugene [ASX:IMU] rose more than 10% on Wednesday after releasing an u...
Read ArticleThe Mayne Pharma Group Limited (ASX: MYX) share price is up a healthy 5% after rocketing today amid...
Read ArticleIt’s been another volatile day of trading as it currently stands this Wednesday. So far in today’s...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and...
Read ArticleShareCafeLunch Report: 10 August, 2022 by Paul Sanger ASX trading lower, but off its lows as tech...
Read ArticleDip-buyers took advantage of early weakness to lift the share market more than 30 points off its low...
Read ArticleThe Imugene Limited (ASX: IMU) share price is soaring on Wednesday. This comes after the company pr...
Read ArticleThe iSelect Ltd (ASX: ISU) share price has skyrocketed on news that the company has received a take...
Read ArticleBeach Energy (ASX: BPT) will sell 3.75 million tonnes of its LNG under a sale and purchase agreement...
Read ArticleThe ASX 200 finishes flat again today Australian consumer confidence down, while business confidenc...
Read ArticleAussie shares eked out a third day of gains as investors mulled mixed leads from the US, a soft trad...
Read ArticleThe S&P/ASX 200 Materials Index is climbing 0.29% today. But what happened to ASX copper shares...
Read ArticleBHP Group Ltd (ASX: BHP) shares are in focus as the company is currently trying to buy the S&P/...
Read ArticleOn Monday, the OZ Minerals Limited (ASX: OZL) share price was the star of the show. The copper mine...
Read ArticleOn Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with the smallest of gains. The b...
Read ArticleShareCafeEvening Report: 8 August, 2022 by Paul Sanger After falling early in the session, the ASX...
Read ArticleIt was a wobbly day on the market for the S&P/ASX 200 Index (ASX: XJO) as energy shares led the...
Read ArticleHighlights The ASX 200 benchmark index closed up today (August 8), gaining 0.071% to end at 7,02...
Read ArticleHighlights The ASX 200 benchmark index closed up today (August 8), gaining 0.071% to end at 7,02...
Read ArticleThe ASX 200 index has finished flat on Monday OZ Minerals rejects a takeover bid from BHP Mining an...
Read ArticleThe ASX 200 extended its advance above 7000 as takeover action in the resources space helped offset...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At...
Read ArticleImugene (IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at t...
Read ArticleThe share market began the week little changed as bond yields surged and weak US equity futures sugg...
Read ArticleShareCafeLunch Report: 8 August, 2022 by Paul Sanger On the ASX this week we kick off the earnings...
Read ArticleShareCafeEvening Report: 4 August, 2022 by Paul Sanger At the closing bell, the S&P/ASX 200 wa...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) slipped ever so slightly on Thursday after major commodity pri...
Read ArticleThe ASX 200 finished little changed after failing to sustain a push above 7000. The Australian be...
Read ArticleThe ASX closes flat today Australia’s trade surplus has hit a new record high Tech shines, while En...
Read ArticleThe S&P/ASX 200 traded briefly above 7000 after oil fell to a six-month low and upbeat US econom...
Read ArticleShareCafeLunch Report: 4 August, 2022 by Paul Sanger The ASX is back in the green today following...
Read ArticleThe Imugene Limited (ASX: IMU) share price has lifted into the green in afternoon trade on Wednesd...
Read ArticleIt hasn’t been a great week thus far for the Appen Ltd (ASX: APX) share price. Appen shares may be...
Read ArticleThe Appen Ltd (ASX: APX) share price is tumbling on Tuesday after the company updated the market on...
Read ArticleThe Appen Ltd (ASX: APX) share price is on watch after the company provided insight on its performa...
Read ArticleASX makes a warm-ish 0.7% start to the month US shares help fuel the rise after Wall Street’s bes...
Read ArticleThe Tyro Payments Ltd (ASX: TYR) share price is rallying well into the green in afternoon trade on...
Read ArticleThe ASX closes slightly higher on Tuesday Energy adds 2.8%, Miners, Resources and Industrials Ahea...
Read ArticleAfter a wobbly start to the day, the S&P/ASX 200 Index (ASX: XJO) posted a gain for the first...
Read ArticleWorld Overnight SPI Overnight 6709.00 + 24.00 0.36% S&P ASX 200 6789.90 – 1.60 – 0.02% S...
Read ArticleShareCafeEvening Report: 25 July, 2022 by Paul Sanger Australian shares have struggled for momentu...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. In afternoon trade,...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a very bumpy start to the trading week this Monday....
Read ArticleIt’s been a rather disappointing start to the trading week so far for ASX shares and the All Ordina...
Read ArticleHighlights The benchmark index was flat during the opening hour but it dropped 0.20% to 6,780.60...
Read ArticleShareCafeEvening Report: 21 July, 2022 by Paul Sanger At the closing bell, the S&P/ASX 200 was...
Read ArticleASX closes 0.30% higher after being in the red Lithium stocks rise on Tesla guidance Woodside down...
Read ArticleShareCafeLunch Report: 21 July, 2022 by Paul Sanger Australian shares are little changed in mixed...
Read ArticleAt lunch on Thursday, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline....
Read ArticleItâs been a ripper month for the Imugene Limited (ASX: IMU) share price. Itâs surged a whopping...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleBenchmark up circa 1%, small caps surge 1.5% Coal miners eclipsed by Whitehaven record profits Kinc...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Mi...
Read ArticleThe Carsales.Com Ltd (ASX: CAR) share price is down 3.83% to trade at $18.59 in late afternoon trad...
Read ArticleHighlights: ASX 200, on Thursday, gained 0.44% driven by Information Technology and Telecommunic...
Read ArticleASX 200 climbs higher despite weak lead from Wall Street Aussie unemployment at lowest since 1974 C...
Read ArticleShareCafeEvening Report: 13 July, 2022 by Melissa Darmawan Australian shares lacked conviction as...
Read ArticleShareCafeLunch Report: 13 July, 2022 by Melissa Darmawan Australian stocks have lacked conviction...
Read ArticleThe ASX closes flat Lithium, e-commerce stocks lose ground Bitcoin back below US$20k Local shares...
Read ArticleA push into defensive assets helped offset declines in mining stocks as consumer sentiment deteriora...
Read ArticleThe Electro Optic Systems Holdings Ltd (ASX: EOS) share price is in the red today while the broad...
Read ArticleThe Aussie share market is heading north today despite Wall Street recording another loss overnight...
Read ArticleHighlights The ASX 200 rose at open on Tuesday. The benchmark index was supported by gain...
Read ArticleASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved in...
Read ArticleAustralian shares retreated with US equity futures and commodity prices as investors reduced their e...
Read ArticleIt has been an encouraging past couple of weeks for the Metcash Limited (ASX: MTS) share price. S...
Read ArticleKermit once sang that it’s not easy being green. If you hold shares in artificial intelligence serv...
Read ArticleShareCafeEvening Report: 8 July, 2022 by Lauren Evans The Australian sharemarket had its best week...
Read ArticleShareCafeEvening Report: 6 July, 2022 by Melissa Darmawan Australia’s trade surplus hit a record h...
Read ArticleThe Imugene Limited (ASX: IMU) share price has steamed ahead in the past week following positive me...
Read ArticleASX 200 rebounds 0.65% on Thursday It comes as Australia records its higher ever monthly trade surp...
Read ArticleThe Link Administration Holdings Ltd (ASX: LNK) share price is up 6.6% in morning trade to $4.08. T...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleThe Tyro Payments Ltd (ASX: TYR) share price is taking off on Wednesday, and itâs not alone in it...
Read ArticleThe Appen Ltd (ASX: APX) share price continued its slide during the month of June. The artificial i...
Read ArticleThe Electro Optic Systems Holdings Ltd (ASX: EOS) share price is up 3.06% in late trading on Tuesda...
Read ArticleAt lunch on Tuesday, the S&P/ASX 200 Index (ASX: XJO) is pushing higher again. The benchmark i...
Read ArticleWorld Overnight SPI Overnight 6538.00 + 1.00 0.02% S&P ASX 200 6612.60 + 72.70 1.11% S&a...
Read ArticleShareCafeEvening Report: 4 July, 2022 by Lauren Evans The Australian sharemarket had a strong star...
Read ArticleASX 200 rallies by 1.20% on Monday This comes after Wall Street begins the new financial year stron...
Read ArticleAussie shares started the week with solid gains as a US market holiday brought a reprieve from overs...
Read ArticleThe Link Administration Holdings Ltd (ASX: LNK) share price is trading lower on Monday morning. In...
Read ArticleShareCafeEvening Report: 1 July, 2022 by Lauren Evans The Australian sharemarket faded into the cl...
Read ArticleASX 200 pulls up lame after a solid early morning run Energy and Materials limp like beaten favouri...
Read ArticleASX finished Friday flat 9 out of 11 sectors rose, but Energy fell by 2.5% as oil prices dip in Asi...
Read ArticleImugene stock rallies on positive Phase 2 trial into its lead drug candidate HER-Vaxx Hexima share...
Read ArticleShareCafeLunch Report: 1 July, 2022 by Melissa Darmawan The Australian sharemarket has started the...
Read ArticleASX closes lower to end the financial year Energy and Miners were the main laggards CBA rises its f...
Read ArticleThe Electro Optic Systems Holdings Ltd (ASX: EOS) share price is trading deep in the red today. At...
Read ArticleTough retail conditions brought on by sky-high inflation have impacted the Woolworths Group Ltd (...
Read ArticleThe Wesfarmers Ltd (ASX: WES) share price is at a very attractive level, in my opinion. Wesfarmers...
Read ArticleWorld Overnight SPI Overnight 6595.00 – 1.00 – 0.02% S&P ASX 200 6700.20 – 63.40 – 0.94%...
Read ArticleAsk A Fund Manager The Motley Fool chats with the best in the industry so that you can get an insig...
Read ArticleShareCafeEvening Report: 29 June, 2022 by Lauren Evans The Australian sharemarket snapped its four...
Read ArticleHighlights ASX 200 closed lower, dropping 63.40 points or 0.94% to 6,700.20. Wall Street fell o...
Read ArticleThe Electro Optic Systems Holdings Ltd (ASX: EOS) share price came out of a trading halt to nosed...
Read ArticleShares of Sayona Mining Ltd (ASX: SYA) are trading deep in the red today. At the time of writing,...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a sizeable decline...
Read ArticleS&P/ASX 200 Index (ASX: XJO) tech shares are feeling the heat today. While the ASX 200 is down...
Read ArticleS&P/ASX 200 Index (ASX: XJO) retail shares are broadly sliding today, despite some upbeat sale...
Read ArticleIt’s a rough day on the market, and these All Ordinaries Index (ASX: XAO) shares are suffering mor...
Read ArticleShareCafeLunch Report: 29 June, 2022 by Melissa Darmawan The rout in Australian shares have contin...
Read ArticleAt lunch on Wednesday, the S&P/ASX 200 Index (ASX: XJO) recovery has run out of steam and the...
Read ArticleImugene’s (ASX: IMU) share price rocketed this week following the announcement its lead candidate HE...
Read ArticleWorld Overnight SPI Overnight 6592.00 – 84.00 – 1.26% S&P ASX 200 6763.60 + 57.60 0.86%...
Read ArticleShareCafeEvening Report: 28 June, 2022 by Paul Sanger The Australian share market has closed highe...
Read ArticleThe Sayona Mining Ltd (ASX: SYA) share price soared today after the company secured a lithium produ...
Read ArticleIf youâre looking to add some high quality shares to your investment portfolio, then you might wa...
Read ArticleThe share market climbed to a two-week high as a rebound in commodity prices helped overcome sceptic...
Read ArticleASX rises 0.86% today despite falls on Wall Street Energy, Miners and Utilities lead the bourse Aus...
Read ArticleMultiple ASX tech shares are having a horror day on the market today. The S&P/ASX All Technolo...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At...
Read ArticleThe Appen Ltd (ASX: APX) share price is lagging the market on Tuesday despite the companyâs silen...
Read ArticleThe share market recovery extended into a fourth session as gains in commodity exporters and defensi...
Read ArticleThe Wesfarmers Ltd (ASX: WES) share price is out of form on Tuesday. In afternoon trade, the conglo...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwise...
Read ArticleThe 4DMedical Ltd (ASX: 4DX) share price is surging today, up 39.6% after posting gains of as much...
Read ArticleAt lunch on Tuesday, the S&P/ASX 200 Index (ASX: XJO) is trading marginally higher after a vol...
Read ArticleHighlights: Australian shares edged higher in opening trade as gains in materials and energy sto...
Read ArticleA positive lead from Wall Street, in which bad news on the economy became good news for stocks, resu...
Read ArticleWorld Overnight SPI Overnight 6593.00 0.00 0.00% S&P ASX 200 6706.00 + 127.30 1.94% S&am...
Read ArticlePowerful rebounds in beaten-down banking and technology stocks powered the share market to its secon...
Read ArticleThe ASX200 is up for a 6-week high today of 2% today US and EU share markets were up 3% and 2.6% re...
Read ArticleASX rallies 2% today on the back of Friday’s strong session on Wall Street Banks, miners, energy an...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is off to a cracking start to the trading week so far this Mon...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a ve...
Read ArticleIt’s been a strong day for the S&P/ASX 200 Index (ASX: XJO) so far this Monday. At the time of...
Read ArticleWhat was the highest ever Xero Limited (ASX: XRO) share price? If you’ve been paying attention to t...
Read ArticleASX copper shares are having a mixed day as the slumping copper price offsets a resurgence in risk...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is exploding today on the back of phase two trial results. I...
Read ArticleShareCafeLunch Report: 27 June, 2022 by Lauren Evans The Australian sharemarket has rallied this m...
Read ArticleA broad rally propelled the share market towards a third day of gains as easing commodity prices and...
Read ArticleIt’s been a cracking start to the trading week so far for ASX shares and the S&P/ASX 200 Index...
Read ArticleIt’s a rough day for the S&P/ASX 200 Index (ASX: XJO) gold miner Northern Star Resources Ltd (...
Read ArticleAt lunch on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a str...
Read Article27 Jun 2022 - A snapshot of the stocks on the move featuring Imugene (ASX:IMU), Centrepoint Alliance...
Read ArticleHighlights: ASX 200 opened sharply higher on Monday amid broad-based rally following Wall Street...
Read ArticleThe Evolution Mining Ltd (ASX: EVN) share price is plummeting on Monday after the company updated t...
Read ArticleImugene (IMU) reports positive and “favourable” survival outcome in final data from its randomised...
Read ArticleASX is set to open sharply higher today after Friday’s big rally on Wall Street US major banks pass...
Read ArticleBy Greg Peel Tech Check The ASX200 slept its way through the first 45 minutes on Friday before sudde...
Read ArticleASX posts its best session in 6 months as banks and energy stocks pace broad rally. Imugene surges o...
Read ArticleThe share market clawed back a fraction of this month’s heavy losses, rising for the first week in t...
Read ArticleThe share market extended its advance for the week as gains in tech and defensive sectors outweighed...
Read ArticleHighlights: The benchmark index ASX 200 edged lower in early morning trade as gains in IT and co...
Read ArticleShareCafeEvening Report: 20 June, 2022 by Lauren Evans The Australian sharemarket remained in nega...
Read ArticleHighlights Australian equity markets extended Tuesday’s losses amid worries over aggressive rate...
Read ArticleThe Imugene Limited (ASX: IMU) share price is struggling on Tuesday despite the companyâs silence...
Read ArticleAustralian stocks were poised to open lower following declines on Wall Street as strong jobs growth...
Read ArticleHighlights At market close, Australian shares dropped 0.8%, or 58.1 points, to 7175.9. Tech sto...
Read ArticleASX closes 0.8% lower BHP-Woodside merged company, Woodside Energy makes its ASX trading debut toda...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of su...
Read ArticleASX 200 finished flattish by 0.08% today Green metal miners plunge after a Goldman Sachs report say...
Read ArticleHighlights The iron ore futures price rose 0.1% to US$133.60 a tonne on Monday as China relaxed...
Read ArticleASX 200 was up 0.56% today Investors flock to gold stocks on flight to safety Tech stocks plunge 2....
Read ArticleShareCafeEvening Report: 24 May, 2022 by Melissa Darmawan Australian shares ran out of steam and c...
Read ArticleASX 200 is down 0.30% The Lottery Corp makes its debut on the ASX Tech weighs heavily after Snap I...
Read ArticleThe share market fell away late in the session as a collapse in US equity futures cooled expectation...
Read ArticleAustralian shares marked time after a poorly-received trading update from US social media giant Snap...
Read ArticleHighlights ASX 200 closed today’s trade merely 3.30 points up at 7,148.90 points. Materials sup...
Read ArticleShareCafeEvening Report: 23 May, 2022 by Melissa Darmawan The Aussie sharemarket lost steam from m...
Read ArticleASX closes flat Mining and Energy lead, while Health and Financials lag Codan, Elders offer strong...
Read ArticleThe share market gave up most of its early gains as overseas crosswinds overshadowed Saturday’s fede...
Read ArticleAustralian immune-oncology stock Imugene [ASX:IMU] released a letter this morning addressing shareho...
Read ArticleThe Imugene Limited (ASX: IMU) share price is soaring ahead today. At the time of writing, Imugene...
Read ArticleThe share market trimmed strong early gains as record Covid cases in Beijing triggered profit-taking...
Read ArticleThe chairman highlighted the company’s strong cash reserves and broad clinical portfolio as assets t...
Read ArticleShareCafeLunch Report: 23 May, 2022 by Melissa Darmawan Australian stocks extend their relief-rall...
Read ArticleShareCafeEvening Report: 19 May, 2022 by Melissa Darmawan More pain for investors as a wave of sel...
Read ArticleHighlights ASX 200 closed 1.6% lower in a session marked by sharp declines for consumer-facing c...
Read ArticleAussie small cap index falls 1.4% The ASX200 down 1.65% Thursday is Arafura Day! Down less than...
Read ArticleThe Imugene Limited (ASX: IMU) share price took off today despite the company’s silence. However, t...
Read ArticleBlue-chip retailers suffered bruising losses after a corporate profit scare pushed the ASX sharply l...
Read ArticleMarkets may be tanking but there are two ASX shares on the All Ordinaries Index (ASX: XAO) that are...
Read ArticleShareCafeLunch Report: 19 May, 2022 by Melissa Darmawan Consumer staples and discretionary stocks...
Read ArticleThe share market gave up almost three days of gains after renewed inflation worries triggered Wall S...
Read ArticleAt lunch on Thursday, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of Wall Street and...
Read ArticleHighlights: The benchmark index ASX200 was down 1.75% in opening trade on Thursday Overnight se...
Read ArticleImugene (IMU) doses its first patient in a phase one clinical trial to shrink advanced tumours The...
Read ArticleASX is set to open higher after a Wall Street rally US Fed chairman Jerome Powell says the Fed will...
Read ArticleShareCafeEvening Report: 16 May, 2022 by Lauren Evans Australian shares struggled to maintain thei...
Read ArticleHighlights ASX 200 closed up, gaining 17.90 points or 0.25% to 7,093.00. China’s decision to lo...
Read ArticleBlue chips pare gains after downbeat Chinese economic data Industrial sector jumps after speculatio...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a reasonably positive start to the week. In afternoo...
Read ArticleShareCafeLunch Report: 16 May, 2022 by Lauren Evans The Aussie sharemarket has advanced this morni...
Read ArticleAt lunch on Monday, the S&P/ASX 200 Index (ASX: XJO) has started the week on a reasonably posit...
Read ArticleA relief rally lifted the ASX 200 back above the 7000 level as a pause in this week’s bloodletting o...
Read ArticleThe share market slumped to a 15-week low before partially recovering as rising US futures sharpened...
Read ArticleFears of a global slowdown helped drive the share market to its lowest since January before a partia...
Read ArticleEmyria announced progress on its MDMA (ecstasy) program Imugene gets green light for a Phase 2 Aust...
Read ArticleImmuno-oncology company Imugene (ASX:IMU) has announced it has received Human Research Ethic...
Read ArticleASX to open extend losses as Wall Street crashes again Oil prices plunge 9% as EU ban on Russian oi...
Read ArticleImugene (IMU) receives Human Research Ethics Committee (HREC) approval to start a phase two clinica...
Read ArticleHighlights ASX 200 finished today’s session down 1.2% or 84.90 points to 7.120, The index was d...
Read ArticleImugene has rejected suggestions it was slow to update the market after copping its second notice fr...
Read ArticleASX 200 extended loss, down by 1.43% All sectors fell except for Energy Tech and Real Estate were t...
Read ArticleThe share market closed at a seven-week low as soft Chinese economic data pushed the dollar below 70...
Read ArticleIn late trade, the S&P/ASX 200 Index (ASX: XJO) looks set to record a disappointing decline. At...
Read ArticleHealthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 yea...
Read ArticleHighlights ASX 200 edged 0.8% higher today, snapping a three-day losing streak and mirroring gai...
Read ArticleSome of the worst-performing corners of the market enjoyed a day in the sun after a relief rally on...
Read ArticleTech and commodity stocks steered the share market towards its first gain of the week following Wall...
Read ArticleAt lunch on Thursday, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and...
Read ArticleAt lunch on Wednesday, the S&P/ASX 200 Index (ASX: XJO) has given back the majority of its morn...
Read ArticleThe Imugene Limited (ASX: IMU) share price is moving in circles during Tuesday afternoon following...
Read ArticleHighlights ASX 200 dropped 1.2% to close 88 points lower at 7347 with all sectors lower. Inves...
Read ArticleASX 200 closed 1.27% lower in a Tech-led rout All 11 sectors were in the red ahead of the RBA meeti...
Read ArticleCentral Banks have their fingers on the fun button this week, and the markets are pricing in the big...
Read ArticleTech stocks slumped to an eight-week low as turmoil on Wall Street and caution ahead of a potential...
Read ArticleThe Imugene Limited (ASX: IMU) share price is deep in the red today following a shock announcement...
Read ArticleImugene (IMU) has scrapped its supply agreement with Merck & Co tradename MSD The parties joine...
Read ArticleThe share market shed 100 points after Wall Street’s worst session since 2020 ensured the new month...
Read ArticleA broad rally carried the share market towards a second day of gains at the end of a challenging mon...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleASX was down for third consecutive day Australia CPI was higher than expected at 5.1% Tech, consume...
Read ArticlePrescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to acti...
Read ArticleASX 200 fell 1.5% and finished the week lower by The Mining Index had its largest weekly drop sinc...
Read ArticleHighlights ASX200 closes trade about 0.56% higher at 7565.20 points today (19 April 2022). The...
Read ArticleLocal blue chips have gone into the Easter Break back in the green. The ASX 200 was up 44.4 points t...
Read ArticleHighlights ASX stocks trade in the green today (14 April 2022, 12 PM AEST) ahead of Easter festi...
Read ArticleHighlights The benchmark ASX 200 index was trading 0.44% up at 7,512 in the first 10 minutes of...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) says City of Hope in the US has dos...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleASX rallies after opening lower today Energy stocks lead the pack on higher oil prices Australia CP...
Read ArticleHighlights The benchmark ASX 200 index was trading 0.25% up at 7,473 in the first 15 minutes of...
Read ArticleHighlights ASX 200 fell 0.4%, or 31.2 points, to 7454, weighed down by losses across healthcare...
Read ArticleASX 200 slipped 0.42% Russia bonds deemed to have defaulted by S&P Afterpay net loss is growing...
Read ArticleThe Australian share market fell to its lowest in two weeks after a global retreat from risk lowered...
Read ArticleA broad sell-off lowered Australian shares in the wake of sharp declines on Wall Street and commodit...
Read ArticleASX 200 healthcare shares have struggled for the past six months, let’s face it. After peaking at 5...
Read ArticleASX was down 0.5% The US Fed signals tightening Aussie payrolls jobs almost flat in March The AS...
Read ArticleThe share market fell for a second day as global financial markets continued to adjust to a fast-cha...
Read ArticleASX 200 is within striking range of record level Tech sector jumps 3% RBA keeps cash rate at 0.1%...
Read ArticleASX 200 extends winning streak US bonds have sharply inverted, sparking concerns of a potential rec...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleHighlights ASX 200 inched 0.2% lower after news that Australia would impose a 35% tariff on Russ...
Read ArticleThe healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two milli...
Read ArticleeInvest MD Camilla Love discusses five ways to spot whether your ESG investment manager is authenti...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on the move today. This comes after the company annou...
Read ArticleThe Uniti Group Ltd (ASX: UWL) share price surged to an all-time high before the company’s shares w...
Read ArticleThe share market logged its highest close in nine weeks as banks and battered growth stocks took ove...
Read Article23 Mar 2022 - Imugene (ASX:IMU) has received approval from the western institutional review board to...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is pushing higher for a second day in a ro...
Read ArticleBanking and tech stocks steered the share market towards its fifth gain in six sessions after a paus...
Read ArticleImugene (IMU) receives the go-ahead to start a phase-one clinical trial of its oncolytic virotherap...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is climbing today on the back of a clinical update from the...
Read ArticleMining, Energy were the two best sectors today Tech was the worst performer following J Powell comm...
Read ArticleASX lost momentum in afternoon session after making early gains Aussie dollar is trading over US 74...
Read ArticleShareCafeWebinar Recap – SNX, VMS, AU1 & IMU Catch up on the full webinar with presentations fr...
Read ArticleShareCafeImugene (ASX: IMU) – Webinar Presentation Leslie Chong – CEO & Managing Director – Imu...
Read ArticleThe share market flew to a one-month high after unemployment fell to its lowest since 2008 and the F...
Read ArticleASX biotech shares have, as a whole, had a remarkably poor run over the last 6 months. Here’s what...
Read ArticleIt was almost a complete reversal of what happened last week, as commodities tumbled and tech stocks...
Read ArticleMining stocks steered the ASX lower as Chinese Covid lockdowns and tentative optimism about Russia-U...
Read ArticleAussie shares retreated as declines in commodity prices weighed on miners and energy producers. T...
Read ArticleClinuvel releases positive preliminary results from pilot study Cann’s Mildura cannabis facility is...
Read Article15 Mar 2022 - A snapshot of the stocks on the move featuring Pushpay (ASX:PPH), Imugene (ASX:IMU) &a...
Read ArticleThe Imugene Limited (ASX: IMU) share price is marching higher in early trade. Imugene shares are up...
Read ArticleImugene (IMU) joins forces with Merck & Co for a new clinical trial collaboration and supply ag...
Read ArticleHighlights The ASX Small Ordinaries index surged 1.12% to 3,215.3 by 12:30 PM AEDT. 99L, OEC an...
Read ArticleHighlights The benchmark ASX 200 was trading 0.88% up at 7,125 in the first 15 minutes of tradin...
Read ArticleOn 8th March 2022, the equity market of Australia ended in red. On the same day, ASX Midcap50 fell b...
Read ArticleHighlights The ASX 200 closed lower by 0.8% this afternoon and has dropped below 7,000. Miners...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) broke below 7,000 points once again as miners and energ...
Read ArticleLocal blue chip shares fell today, as risk-off sentiment prevails across Asia following the latest d...
Read ArticleEnergy sector rises 5% as oil prices go nuts The benchmark Brent crude continued its rise in Asian t...
Read ArticleThe dollar rose and stocks fell as extreme moves in commodity prices drove Asian markets and US and...
Read ArticlePatents, partnerships, dose safety and ongoing candidate trials are some of the hallmarks of the com...
Read ArticleThe share market fell steadily all morning as the threat of embargoes on Russian energy exports drov...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleThe major miners dug the share market out of a hole after soaring commodity prices helped drive Wall...
Read ArticleIt was all about commodities today, as the Bloomberg Commodity Spot Index recorded its biggest one-d...
Read ArticleWorld Overnight SPI Overnight 6997.00 – 49.00 – 0.70% S&P ASX 200 7096.50 + 47.40 0.67%...
Read ArticleHighlights The ASX 200 closed 0.7% higher to 7,096.50. Tech shares dominated the session, and t...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) posted its third day in a row of gains as the Reserve B...
Read ArticleAustralian stocks rose for a third session after the Reserve Bank renewed its pledge to be patient o...
Read ArticleAustralian stocks rose for a third day as buyers continued to discount the threat of significant eco...
Read ArticleHighlights The benchmark ASX 200 surged 1.1% to 79.3 points in the first 15 minutes of trading....
Read ArticleRisk-off moves on global financial markets curbed a second day of share-market gains as investors fr...
Read ArticleImugene (IMU) records an income of more than $5.34 million for the half-year ending December 31, 20...
Read ArticleAustralian stocks rose for a second session, hampered by a slump in US futures after the West turned...
Read ArticleThe ASX appeared set for a blistering start to the week following the Dow’s best session in more tha...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) avoided negative territory after its worst fall in 17 m...
Read ArticleLocal stocks performed admirably on Friday considering a trans-national conflict is in full swing, b...
Read ArticleThe share market closed out its worst week since 2020 with a modest rebound as fighting in Ukraine a...
Read ArticleA massive overnight reversal on Wall Street and a strong trading update from Afterpay’s US parent co...
Read ArticleHighlights In one of its worst showings of the year, the ASX 200 dropped below 7,000 as the Ukra...
Read ArticleHighlights The ASX 200 closed 1% lower, dropping 72.30 points to 7,161.30. US futures fell on f...
Read ArticleThe share market closed at a two-week low after a dramatic escalation in the Russia-Ukraine crisis t...
Read ArticleGeopolitical concerns continue to be the main driver for the markets, with the ASX 200 falling by 1....
Read ArticleDisclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and ass...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) managed to eke out another green day after swinging vio...
Read ArticleWorld Overnight SPI Overnight 7206.00 + 3.00 0.04% S&P ASX 200 7284.90 + 78.00 1.08% S&a...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleOn 16th February 2022, the equity market of Australia ended the trading session in green. On the sam...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) put the foot on the gas amid a flurry of earnings that...
Read ArticleHighlights Australian shares climbed over 1% to 7284.9, boosted by strong gains from companies t...
Read ArticleIt was mostly about corporate earnings today as investors digested a smorgasbord of half yearly resu...
Read ArticleHighlights The ASX 200 closed 0.3% higher with energy stocks rising on a 7-year high for oil of...
Read ArticleLocal shares moved higher today. Investors took to safety, betting on gold producers on concerns tha...
Read ArticleAussie shares overcame weak leads and early pressure to start the week higher as geopolitical concer...
Read ArticleAustralian stocks edged higher following a volatile morning as investors weighed geopolitical tensio...
Read ArticleOn 9 February 2022, the equity market of Australia settled in green. On the same day, ASX Midcap50 w...
Read ArticleHighlights Australian shares advanced 0.98% to 7,257, boosted by a strong session for the financ...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) climbed further out of its recent January dip. At the e...
Read ArticleImugene company director Dr Jens Eckstein acquired 15 million shares, displaying his confidence in t...
Read ArticleAussie shares climbed 1.13% higher today, boosted by a tech stock rally. The XIJ tech index rose by...
Read ArticleV-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel...
Read Article“Commercial success outside these financially modelled programs would serve as potential upside to o...
Read ArticleHighlights The ASX 200 rallied toward the close, paring back losses that stood as much as 0.5% b...
Read ArticleThe ASX 200 got off a slow start but held its ground throughout Thursday trade, to finish 0.14% lowe...
Read ArticleA Facebook-fuelled collapse in US futures triggered heavy selling in Australian tech stocks, pulling...
Read ArticleAussie shares retreated from a one-week high after downbeat earnings from Facebook and Paypal trigge...
Read ArticleOn 01st February 2022, the equity market of Australia closed in green. On the same day, ASX Midcap50...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) rallied off the back of a strong showing on Wall Street...
Read ArticleASX large caps posted steady gains in Tuesday trade, as tech stocks and financials gained while reso...
Read ArticleDr Cha will lead the company’s global clinical development efforts and medical affairs at a pivotal...
Read ArticleThe share market retreated ahead of a week of risk events including a Reserve Bank policy meeting an...
Read ArticleImmuno-oncology company Imugene (IMU) is granted a Japanese patent which protects its cancer-treati...
Read Article“Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese pate...
Read ArticleOn 28th January 2022, the stock market in Australia ended in green. On the same day, ASX 20 rose by...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) fought back against the selling pressure throughout the...
Read ArticleWe’ve all gone a little bit crackers on Friday – or as the Kiwi’s like to say in French – un peu fou...
Read ArticleKey Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is rebounding strongly from recent decline...
Read Article28 Jan 2022 - Bio-tech company Imugene (ASX:IMU) has made two announcements today regarding its HER-...
Read ArticleKey points Imugene share price soared 5% on the back of European patent approval This is further i...
Read ArticleClinical stage immuno-oncology company Imugene (IMU) granted a European patent for its HER-Vaxx imm...
Read ArticleThe patent protects the company's gastric cancer treatment, HER-Vaxx, for method of composition and...
Read ArticleASX is up in a wild session that has seen big swings. Ramelius tumbles as WA's closed border hits gu...
Read ArticleHighlights Australian shares fell 0.5%, or 36.3 points to 7139.5 today. Investing sentiment tod...
Read ArticleFears of a market meltdown subsided early today as the ASX 200 fell by just 0.5%, lifted by the boun...
Read ArticleHighlights Today, the ASX 200 closed sharply lower; the broad-based decline was led by the mater...
Read ArticleASX health stocks (XHJ index) are down .99% today but faring better than the ASX 200 which has falle...
Read ArticleThe company thanked Dr Laeufle for her role in advancing Imugene's clinical activities - it is now i...
Read ArticleHighlights The ASX 200 closed 1% lower today, thanks to a sell-off in US stocks overnight. Inve...
Read ArticleA risk-off down-shift on global markets pushed Australian shares to their weakest close of the year...
Read ArticleOn 18th January 2022, the equity market of Australia closed in red. On the same day, ASX Midcap50 ro...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) slipped to the downside after starting off in the green...
Read ArticleLocal markets were somewhat directionless today as Wall Street took time out for the Martin Luther K...
Read ArticleHighlights The ASX 200 added 48.8 points and closed at 7438.9 today, thanks to a strong session...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) pulled higher in a similar fashion to Wall Street’s sho...
Read ArticleThe ASX 200 was up 0.59% today after a flat start to the week. Both US and EU stocks rose after US F...
Read ArticleThe money will support the immuno-oncology company’s commercial and clinical milestones, several of...
Read ArticleHighlights The ASX 200 fell 2.7%, following a sharp drop for US stocks overnight after Federal...
Read ArticleThe ASX 200 plummeted ~2.7% today, with a huge 6% selloff in the Tech sector weighing heavily on the...
Read ArticleThe Imugene Limited (ASX: IMU) share price is sliding in negative territory today despite a positiv...
Read ArticleImugene (IMU) receives a South Korea patent grant for its HER-Vaxx Immunotherapy The patent will pr...
Read ArticleImugene’s HER-Vaxx candidate is in development for the HER-2 positive gastric cancer market, a type...
Read Article2021 came with many ups and downs, both on and off the market, but these 5 ASX shares weathered the...
Read ArticleOn 05 January 2022, the equity market of Australia closed in red as healthcare sector witnessed sell...
Read ArticleThe Pro Medicus Limited (ASX: PME) share price sunk almost 10% on Wednesday despite no news being r...
Read ArticleHighlights Australian shares dropped 0.3% to 7565.8 as heavy losses by healthcare and technology...
Read ArticleAustralian stocks flirted with record levels before fading to their second loss in nine sessions as...
Read ArticleAfter lifting 2% yesterday, the ASX 200 retreated 0.3% today driven by a selloff in tech stocks. The...
Read ArticleThe S&P/ASX 200 climbed to within 13 points of a record before turning lower as the Santa rally...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) cemented its second-highest level on record as it kicke...
Read ArticleThe first trading day of 2022 saw the ASX 200 surging by 2% to its highest level since August. All e...
Read ArticleThe first session of 2022 delivered the share market’s strongest advance in more than a year. The...
Read ArticleThe benchmark ASX 200 was up by 2% on the first day of trading in 2022. The ASX Emerging Companies I...
Read ArticleThe share market flew to a four-month high after Wall Street ended its first session of 2022 at a re...
Read ArticleThe Imugene Limited (ASX: IMU) share price is climbing today following a development in the company...
Read ArticleThe price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the ma...
Read ArticleThe ASX 200 Health Index (XHJ) is trading higher by 0.30% at the time of writing, compared to the br...
Read ArticleImugene (IMU) has completed the Phase 1a monotherapy dose escalation of PD1-Vaxx and will now go on...
Read Article“Our Phase 1a trial has been open 12 months and I’m pleased with both the pace of development and th...
Read ArticleIt was the last full trading session for the ASX in 2021, and the local benchmark index closed flatt...
Read ArticleThe Santa rally overcame a mid-session wobble to deliver investors a sixth straight rise and a 16-we...
Read ArticleThe share market drifted lower amid signs of buyer fatigue following a five-session rally across the...
Read ArticleHighlights The ASX 200 was trading 1.6 points up at 7,511.4 in early trade. As Asia markets clo...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleHighlights The ASX 200 advanced 0.1 per cent, or 9.8 points, to 7364.8 today. Asian shares wer...
Read ArticleA strong tech-led rebound on Wall Street overnight wasn’t enough to provide a boost for the ASX 200....
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a decent day of trading on the markets this Tuesday...
Read ArticleThe share market shrugged off weak leads and record Covid numbers in NSW as robust consumer confiden...
Read ArticleThe ASX 200 started Christmas week in the red today, down by 0.27%, as investors turned increasingly...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) took a trip to the downside amid key data from the Rese...
Read ArticleThe Tech sector weighed heavily on the local index today and was down by more than 2.5%, dragging th...
Read ArticleThe ASX 200 eked out a small Tuesday gain, as local stocks drifted sideways following a weak lead fr...
Read Article“Attaining the key Chinese patent is an important milestone. This adds to Imugene’s portfolio of B-c...
Read Article“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on course to start the week with a gain. In early tra...
Read ArticleImugene (IMU) receives US FDA Investigational New Drug (IND) approval for two new drug candidates...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) experienced a bumpy ride as it bounced between positive...
Read ArticleThe ASX 200 finished lower by 0.28% today, as investors turn cautious ahead of the Fed’s CPI release...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At th...
Read ArticleThe Imugene Limited (ASX: IMU) share price is up today on the back of a positive cancer treatment u...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader inde...
Read ArticleImugene (IMU) doses its second patient in the phase one clinical trial of its CHECKvacc drug candid...
Read Article“We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed e...
Read ArticleShares in biopharma company Imugene Limited (ASX: IMU) are inching lower in afternoon trade and are...
Read ArticleIn the December 2021 quarterly rebalance Imugene will be added to the S&P/ASX 200 Index and Arch...
Read ArticleAlloggio Group (ASX:ALO), didn’t have a positive debut on the ASX last week but that didn’t stop one...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) made an effort to recoup its early morning losses but w...
Read ArticleThe ASX 200 closed in the red for the third time in four sessions on Thursday, but an afternoon rall...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) partially bounced back from yesterday’s Omicron-induced...
Read ArticleAfter climbing more than 1% in morning trade, local large caps lost ground in the afternoon session...
Read ArticleHe’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radi...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe Imugene Limited (ASX: IMU) share price is flat at 52.5 cents in early trade today after finishi...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleAfter falling by ~0.8% on Tuesday, the ASX 200 struggled for traction in Wednesday trade to finish 0...
Read ArticleAs Stockhead’s Josh Chiat reported this morning, reports of an industrial production slowdown in the...
Read ArticleThe success of trials of the company's cancer immunotherapy drug to date has encouraged Roth Capital...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) managed to deliver a positive session despite weakness...
Read ArticleThe ASX 200 rebounded by 0.13% today, after posting losses over the last two days. Healthcare, Real...
Read ArticleImugene (ASX:IMU) has announced a new supply agreement with Pfizer and Merck for a trial inv...
Read ArticleThe ASX 200 continues its slide, down by 0.63% today after a 0.67% fall yesterday. Stocks were sold...
Read ArticleHighlights Imugene shares rose nearly 9% on signing a new clinical trial supply agreement. OZ M...
Read ArticleThe Imugene [ASX:IMU] share price is up 6% following a supply agreement update. Imugene, the biotech...
Read ArticleAfter making a steady start to the week on Monday, the ASX 200 ran into a roadblock on Tuesday to fi...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) came under pressure as the RBA noted better-than-expect...
Read Article16 Nov 2021 - A snapshot of the stocks on the move, featuring Imugene (ASX:IMU), Beach Energy (ASX:B...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and tumbling lower. At the...
Read ArticleHighlights The ASX 200 had dropped as much as 0.6% by mid-session on Tuesday. Barring A-REIT, a...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader inde...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is surging in morning trade, up 9% at time of writing. Below...
Read Article16 Nov 2021 - Bio-tech company Imugene (ASX: IMU) has announced a new clinical trial supply agreemen...
Read ArticleImugene (IMU) secures a new clinical trial supply agreement with Pfizer Inc and Merck KGaA, Darmsta...
Read Article“HER-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with metastatic...
Read ArticleWall Street retreats slightly All three US stockmarket benchmarks were slightly lower on Monday – th...
Read ArticleHighlights The ASX 200 has delivered a return of over 11% so far this year as the domestic econo...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a positive note, breaking a four-d...
Read ArticleThe ASX 200 finished the week with some strong Friday vibes to close almost 1% higher. It was a comm...
Read ArticleHighlights Despite pandemic, few ASX companies have delivered outstanding returns. LTR, ACB, P...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) has delivered its third consecutive day of gains. At th...
Read Article"Our 12-month price target of A$0.62 is based on a DCF analysis using a 15% discount rate ... We arr...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) followed the lead of Wall Street with another positive...
Read ArticleLocal large caps posted a solid day of trade on Thursday, as the ASX 200 finished 0.36% higher. Gain...
Read Article“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Austral...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) delivered a positive session for investors. At the end...
Read ArticleThe ASX 200 responded to record high levels on Wall Street overnight, rallying by 0.89% to close at...
Read ArticleImugene (ASX:IMU) has announced a new collaboration under which it will evaluate its CD19 on...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) kicked off the new week with a green session. At the en...
Read ArticleFollowing Wall Street’s record levels on Friday, the ASX 200 rebounded to rise by 0.6% today. All se...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a soli...
Read ArticleShares in biotech company Imugene Limited (ASX: IMU) are lifting in afternoon trade today and are c...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 1.30% at the time of writing, compared to the broader index...
Read ArticleImugene (IMU) teams up with US-based Eureka Therapeutics to test a combination of clinical treatmen...
Read ArticleThe collaboration has the potential to address the lack of tumour-specific targets in solid tumours...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) slipped lower following in the footsteps of last night’...
Read ArticleTrading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers a...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) started the week off with a positive move. The benchmar...
Read ArticleGrowing concerns of runaway inflation and a sooner-than-expected rate hiked spooked tech stocks glob...
Read ArticleOne of the biggest exploration success stories of the decade prior to COVID-19 was copper play Sandf...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the City of Hope...
Read ArticleThe odds are stacked against small cap ASX stocks growing into the top echelon of the bourse – the A...
Read ArticleMoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and ana...
Read Article“It’s a proud moment to see CF33-hNIS-antiPDL1 (CHECKvacc) continue its progression and have this Ph...
Read ArticleImugene (IMU) announced that cancer and research centre, City of Hope, has dosed the first patient...
Read ArticleThe ASX 200 posted its second day of steady gains, although the drivers were broadly the reverse of...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) finished slightly lower after paring earlier gains. The...
Read ArticleThe S&P/ASX 300 Index (ASX: XKO) is climbing in early afternoon trade, after spending the morni...
Read ArticleToday, the S&P/ASX 200 Index (ASX: XJO) dealt another day of green to finish the week. The benc...
Read ArticleThe benchmark ASX 200 mounted a last 30-minute rally index to edge just slightly lower on Wednesday,...
Read ArticleThe ASX 200 slumped by 0.28%, despite NSW pubs, retail and hairdressers reopening for business. The...
Read ArticleThe market is maintaining its gains today and is up 0.9% so far this week following 4 weeks of losse...
Read ArticleShares in the immunotherapy company Imugene Limited (ASX: IMU) are 7.8% higher in afternoon trade a...
Read ArticleThe ASX 200 followed Wall Street lower in Tuesday trade, in line with what looks like the emergence...
Read ArticleThe S&P/ASX 200 index (ASX: XJO) has started the week on a downward trend, trading 0.36% lower...
Read ArticleLocal markets looked brighter today. US share markets rebounded on Friday. Global oil prices also ro...
Read ArticleThe S&P/ASX 300 Index (ASX: XKO) is pushing upwards today, recovering lost ground from Friday’s...
Read ArticleAs we make our way through the first half of FY22, equity markets have begun to shake up somewhat i...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe S&P/ASX 300 Index (ASX: XKO) is back in negative territory on Friday, losing ground from ye...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleMarkets were calm and collected on Thursday, as the ASX 200 climbed by more than 1% following a stro...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced it has received a not...
Read ArticleThe Imugene Ltd (ASX: IMU) share price is edging higher in afternoon trade on Wednesday and now tra...
Read ArticleThe S&P/ASX 200 index (ASX: XJO) has spent the day in the green and is currently 0.5% higher at...
Read ArticleThe company’s HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that over-expr...
Read ArticleThe ASX 200 lost 0.92% today, taking the benchmark index lower by 0.20% for the week. The local mark...
Read ArticleLeader of the ASX health stocks today is Imugene (ASX:IMU) up 4.11% after announcing plans to presen...
Read ArticleThe S&P/ASX 300 Index (ASX: XKO) is charging higher today following a mixed daily movement thro...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThere was broad based selloff across ASX blue chips today, with all 11 sectors falling into the red....
Read ArticleHighlights The Australian share market is expected to fall again on Thursday after US and Europe...
Read ArticleThe ASX 200 made a little comeback in afternoon trade, but still traded flat on the day as local sto...
Read ArticleThe benefit to stock prices on inclusion in the index is significant because all the ETF’s that trac...
Read ArticleThe S&P/ASX 300 Index (ASX: XKO) is in reverse in afternoon trade today. At the time of writing...
Read ArticleThe clinical-stage immune-oncology company is sitting on $130 million in cash, and Bell Porter sees...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleThe Imugene [ASX:IMU] share price is floundering today on the back of an announcement regarding its...
Read ArticleThe ASX 200 index fell today, despite the latest Australian GDP data showing a 0.7% growth in the l...
Read ArticleHER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that overexpress the HER-2/n...
Read ArticleShareCafeAustralia… One Hour In… ASX200 down 58 ASX200 down 58 points (0.8%) to 7476. BHP (-0.9%)...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on the move on Wednesday morning. In early trade, the...
Read ArticleLocal stocks notched up a steady day of trade on Tuesday, as global markets grind ahead in the wake...
Read ArticleThe CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure canc...
Read ArticleThe ASX 200 made a positive start to the week, rising by 0.22%. The mining sector was the clear winn...
Read ArticleThe Imugene Ltd (ASX: IMU) share price has surged more than 7% on Monday after the immuno-oncology...
Read ArticleClinical results continue to indicate that PD1-Vaxx is showing early signs of an immune response in...
Read ArticleAfter three straight gains, the ASX 200 lost ground on Thursday as local markets edged lower. Last w...
Read ArticleThe ASX 200 closed higher on the day, but it was outpaced by the smaller end of town as the ASX micr...
Read ArticleIncannex lodged extensive registration form with SEC. A strategic dual-listing will give Incannex ac...
Read ArticleThe clinical-stage immune-oncology company will use the funds to support work across its three novel...
Read ArticleClinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has filed a registr...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticlePaul Hopper has been behind a number of successful oncology biotechs, and his latest venture is one...
Read ArticleThe clinical-stage immune-oncology company announced it would collaborate with the NASDAQ-lister las...
Read ArticleThe ASX 200 traded sideways today, and ended the day flat, rising just 2 points to 7,540. Financials...
Read ArticleThe company is well-funded to deliver on commercial and clinical milestones including the developmen...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At th...
Read ArticleASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which ro...
Read ArticleCombining Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy has t...
Read ArticleShareCafeAustralia… One Hour In… ASX200 down 4 ASX200 down 4 points to 7499. Bendigo and Adelaide...
Read ArticleThe Imugene Limited (ASX: IMU) share price is pushing higher on Thursday morning. At the time of wr...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleThe ASX200 finished 0.22% lower in Tuesday trade, dragged down by a flat session for the big miners...
Read ArticleThe cavalcade of life science initial public offers (IPOs) and ASX listings shows few signs of reced...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe ASX200 chalked up another day of gains in Thursday trade, and once again it was resources leadin...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the...
Read ArticleInvestor funds continue flowing into ASX listed biotechnology shares this year, with a total of alm...
Read ArticleThe biotech’s multi-million-dollar capital raise will support development opportunities across its c...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleThe ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of...
Read ArticleThe ASX 200 touched intraday record highs, but could not hold on and closed the day just shy of its...
Read ArticleSecurities will remain halted until Thursday, July 29, 2021, or when an announcement is released to...
Read ArticleBell Potter is in the market raising capital for oncolytic immuno-oncology biotech Imugene, which is...
Read ArticleShareCafeAustralia… One Hour In… ASX200 up 20 ASX200 up 20 points (+0.3%) to 7414. BlueScope (+2....
Read ArticleLocal stocks continued to edge higher to end the week, although there was a notable tone of caution...
Read ArticleIn late afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a s...
Read ArticleThe clinical-stage immuno-oncology company has progressed work across its cancer therapy candidates...
Read ArticleAfter a rough couple of days, local stocks got back in the saddle on Wednesday as most large cap sec...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleMost ASX large cap sectors finished in the red today, in a topsy-turvy session which saw the ASX200...
Read ArticleThe ASX 200 edged 0.26% lower after trading flat at lunch time, despite stronger than expected emplo...
Read ArticleThe ASX 200 finished higher by 0.37% today, with the Tech sector the only sector in the red, falling...
Read ArticleHealthcare is a constantly changing industry in which you may be asking yourself if your investment...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleImugene is a clinical-stage immuno-oncology company developing a range of new and novel immunotherap...
Read ArticleAs we’ve covered extensively on the Fool over the past week, the S&P/ASX 200 Index (ASX: XJO) h...
Read ArticleImugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherap...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to end the week on a solid not...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has just finished up one of its best financial years ever. As...
Read ArticleImugene managing director and chief executive officer Leslie Chong called the approval a “major mile...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on course to end the week on a positive note. In morn...
Read ArticleWall Street higher as US jobless claims plunged All the three major US benchmarks rose overnight, af...
Read ArticleIn FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over...
Read ArticleShares in ASX biotech companies Anteotech Ltd (ASX: ADO), Imugene Ltd (ASX: IMU) and Little Green P...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleShareCafeHidden Gems Webinar Recap: RAC, IMU, AUA & BRN Catch up on the full webinar with pres...
Read ArticleShareCafeA clinical stage immuno-oncology company Imugene (ASX: IMU) – Hidden Gems Webinar. Present...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleShares in Imugene Limited (ASX: IMU) continue to be among the most traded shares on the market. Unf...
Read ArticleThe company believes new chief business officer Dr Monil Shah will make a valuable contribution to a...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has slipped today after a strong initial push into positive te...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) had a rather flat day today. The index finished up 0.15% at 7,...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading d...
Read ArticleIt has been a very volatile day for the S&P/ASX 200 Index (ASX: XJO) on Tuesday. However, in af...
Read ArticleLast month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks the...
Read ArticleThe most notable directors trade over $100,000 in the last fortnight was a $4 million trade by Yaniv...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleBy combining its cancer-killing virus with CAR T therapy, Imugene hopes to destroy solid tumours.
Read ArticleThe Imugene Limited (ASX: IMU) share price has taken a large hit today. Shares were down over 30% ea...
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 14 ASX200 up 14 points (0.2%) to 7107. AMP (+4.4%); is be...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleThe company has enhanced its portfolio with a novel CD19 expressing oncolytic virus from City of Hop...
Read ArticleThe Imugene Limited (ASX: IMU) share price has continued its positive run on Tuesday. At the time o...
Read ArticleBiotech Global Health (ASX:GLH) topped this week’s Running Hot list, in the wake of more steady gain...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe Imugene Limited (ASX: IMU) share price hit an all-time high of 41 cents in intraday trade today...
Read ArticleSummary Extending gain for the third session, the ASX200 trades higher by 70 points or 0.51% at...
Read ArticleA series of ASX announcements has attracted investors to the biotech sector today, lifting the share...
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 43 ASX200 up 43 points (0.6%) to 7067. Boral (+0.6%); sai...
Read ArticleThe Imugene Limited (ASX: IMU) share price is leaping higher today on the back of news the immuno-o...
Read ArticleThe company has enhanced its portfolio with novel CD19 expressing oncolytic virus from City of Hope...
Read ArticleUS and European stock markets down to start the week All major indices in US and Europe were down on...
Read ArticleThis week’s Hot Money is more or less brought to you by the good folks at Mindax (ASX:MDX), with a n...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleGoogle April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. J...
Read ArticleHER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HE...
Read ArticleThe important clinical endpoint of Progression Free Survival (PFS) has been met after the statistica...
Read ArticleShareCafeAustralia…1 hour in… ASX200 down 65 ASX200 down 65 points (0.9%) to 6952. BHP (-1.8%); r...
Read ArticleImugene shares have hit a fresh all-time high this morning after the Sydney biotech said its HER-Vax...
Read ArticleIn afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week w...
Read ArticleShareCafeAustralia…1 hour in… ASX200 down 11 ASX200 down 11 points (0.2%) to 6893 BHP (-0.2%); sa...
Read ArticleSingapore-based Asian American Medical Group (ASX:AAJ) was among the small cap names that ran red ho...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSmall caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordi...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike....
Read Article07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an indepen...
Read ArticleImugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its ca...
Read ArticleThe Imugene Limited (ASX: IMU) share price is through the roof today, breaking record highs. At the...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleSource: Enjoy The Life, Shutterstock Summary ASX 200 increased 0.8% on Friday, however it edged...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on the move today. This comes after the company annou...
Read ArticleThe company is a clinical-stage immuno-oncology company developing a range of new and novel immunoth...
Read ArticleThe Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company recei...
Read ArticleThe CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has rec...
Read ArticleSummary Chimeric Therapeutics commenced trading on the ASX today following the successful comple...
Read ArticleSummary Imugene Limited (ASX:IMU) has completed the recruitment of patients under its ongoing HE...
Read ArticleImugene Ltd [ASX:IMU] certainly finished 2020 with a bang. With a 5% lift in the IMU share price thi...
Read ArticleImugene Limited (ASX: IMU) shares have jumped by 5% in trading so far today after the biotechnology...
Read ArticleShareCafeAustralia…One Hour In…ASX up 85 points ASX200 up 85 points (1.3%) to 6692. Market tracking...
Read ArticleThe Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activa...
Read ArticleThe Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month p...
Read ArticleSummary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first coho...
Read ArticleThe clinical-stage immune-oncology company has enrolled the first three patients in the first low do...
Read ArticleSummary Imugene Limited (ASX:IMU) has received an R&D tax refund of ~$4.82 million under gov...
Read ArticleReceiving the $4,823,466 million in additional funding will further support the company's commercial...
Read ArticleBell Potter has raised its valuation of Imugene to 17 cents from 5 cents and has maintained its buy...
Read ArticleSummary Imugene Limited (ASX:IMU) has dosed its first patient in PD1-Vaxx Phase 1 trial in Melbo...
Read ArticleSydney biotech company Imugene (ASX:IMU) says it has dosed its first patient with its drug candidate...
Read ArticleShareCafeAustralia…One Hour In…ASX up 33 points ASX200 up 33 points (0.5%) to 6551. AUB (-1.6%); wi...
Read ArticleThe first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients...
Read ArticleSummary Imugene Limited (ASX:IMU) has recently shared promising interim data from its continuing...
Read ArticleThe share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year. Im...
Read ArticleThe Imugene Ltd [ASX:IMU] share price is trading 15% higher at time of writing. Rising on the back o...
Read ArticleThe IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall...
Read ArticleSummary Imugene has received the US FDA IND approval to kick-start Phase 1 clinical trial of PD1-...
Read ArticleShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); say...
Read ArticleUS FDA approval of the IND allows Imugene to initiate patient recruitment and dosing in its USA Phas...
Read Articleul> Post delivering a solid performance in the June 2020 quarter, Imugene Limited (ASX:IMU) ha...
Read ArticleDuring the September quarter, the clinical-stage immuno-oncology company continued to progress clini...
Read ArticleThe company is well-funded to deliver on commercial and clinical milestones including the developmen...
Read ArticleSummary Imugene has attained a core patent in the largest pharmaceutical market of the world. Th...
Read ArticleImugene's oncolytic viruses are designed to infect, replicate in, and kill cancer cells, leaving hea...
Read Article02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US Unite...
Read ArticleThe company recently boosted its balance sheet with a $5.7 million underwriting agreement to support...
Read ArticleSummary Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of it...
Read ArticleThe company recently entered into an agreement to underwrite outstanding listed options which provid...
Read ArticleNSW-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has secured an unde...
Read ArticleThe agreement with Bell Potter further strengthens the company’s financial position building on the...
Read ArticleSummary Imugene has received first ethics approval in the US to start PD1-Vaxx’s Phase I trial....
Read ArticleSite activation and patient recruitment will proceed after FDA IND approval scheduled for the fourth...
Read ArticleIn a latest update, the biotech company Imugene Limited (ASX:IMU) has published its Annual Report fo...
Read ArticleThe stock of Australian clinical-stage immuno-oncology company, Imugene Limited (ASX:IMU) traded ~1....
Read ArticleThe ethics approval represents the third independent review of PD1-Vaxx pre-clinical safety and effi...
Read ArticleSummary Imugene received US FDA guidance on the development pathway for VAXinia (CF33-hNIS). FDA...
Read ArticleThe FDA provided feedback on the non-clinical development pathway and adaptive phase one clinical de...
Read Article“We’re sorry.” Two words rarely heard from company boards, and even more rarely in annual reports. B...
Read ArticleLast month, Imugene received Human Research Ethics Committee approval to begin a phase-I clinical tr...
Read ArticleClinical stage immuno-oncology company, Imugene Limited (ASX:IMU) marked an uptick of ~22.6 per cent...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSummary Imugene has received a second human research ethics approval to kickstart its Phase I cli...
Read ArticleImmuno-oncology company Imugene (ASX: IMU) received a timely regulatory boost courtesy of a second H...
Read ArticleThe ethics approval represents the second independent review of PD-1 Vaxx pre-clinical safety and ef...
Read ArticleShareCafeAustralia…1 Hour In…ASX Up 2 Points – Bluescope (-1.5%); expects FY earnings to be around $...
Read ArticleA quick wrap of the ASX’s key winners and losers on Wednesday, July 15. Data is taken after the mark...
Read ArticleSummary Imugene has attained human research ethics approval for commencement of PD1-Vaxx’ Phase 1...
Read ArticleEthics approval is confirmation Imugene has completed all the necessary pre-clinical safety and effi...
Read ArticleShareCafeAustralia…One Hour In…ASX Down 47 Points – Breville Group (+4%); big broker upgrade. – Imug...
Read ArticleSummary Backed by an international leadership team with extensive commercialisation expertise in...
Read ArticleSummary Imugene?s preclinical research associated with mimotope vaccines targeting immune checkpo...
Read ArticleThe research has identified mimotope peptides that when incorporated into Imugene’s proprietary immu...
Read ArticleHER-Vaxx is Imugene’s lead cancer immunotherapy candidate and is currently treating patients in a ph...
Read ArticleClinical stage Australian immuno-oncology company, Imugene Limited (ASX:IMU) is set to kickstart two...
Read ArticleThe Independent Data Monitoring Committee (IDMC) members have no safety concerns regarding B-cell im...
Read ArticleThe Independent Data Monitoring Committee’s role is to review study data and conduct a formal indepe...
Read ArticleAustralia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) will present the clini...
Read ArticleThe first-in-human phase 1 study of Vaxinia is in patients with advanced or metastatic melanoma, non...
Read ArticleThe company is developing a range of new and novel immunotherapies that seek to activate the immune...
Read ArticleAustralian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) is actively...
Read ArticleThe company is developing a range of new treatments that seek to activate the immune system of cance...
Read ArticleThe company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric ca...
Read ArticleThe company is developing a range of treatments to activate the immune system of cancer patients.
Read ArticleThe ASX is cracking down on biotech and health companies disclosures around possible coronavirus-lin...
Read ArticleThe company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric ca...
Read ArticleThe clinical stage immuno-oncology company is developing a range of new treatments seeking to activa...
Read ArticleThe company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric ca...
Read ArticleAustralian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has released...
Read ArticleThe company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric ca...
Read ArticleThe company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (...
Read ArticleImugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx
Read ArticlePre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finis...
Read ArticleImugene (IMU) will trial its cancer immunotherapy treatment, PD10Vaxx, to patients in North America...
Read ArticleImmuno-oncology company Imugene (ASX: IMU) is set to advance its PD1-Vaxx cancer immunotherapy by tr...
Read Article28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx...
Read ArticleA Smash Hit by Imugene: Received Core US Patent for HER-Vaxx
Read ArticleThe health sector was the most successful sector on the ASX in 2019. Various small caps made several...
Read ArticleThe patent provides method of composition and method of use protection to 2036.
Read Article14 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) has received the US patent for its HER-VAxx c...
Read ArticleImugene (IMU) has received a Notice of Grant from the United States Patent and Trademark Office to...
Read ArticleImugene (ASX: IMU) has received a strong boost in protecting its intellectual property for the next...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleYou don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the...
Read ArticleAustralia-based clinical stage immuno-oncology player, Imugene Limited (ASX: IMU) has recently annou...
Read ArticleDr. Auer heads a research laboratory and is the principle investigator in related clinical trials.
Read ArticleNew Zealand’s medicines regulator has recommended the country fall in line with Australia’s new code...
Read ArticleClinical-stage immuno-oncology player, Imugene Limited (ASX: IMU) recently notified that it has rece...
Read ArticleThe placement raised A$24.6 million and was well supported by existing investors and new sophisticat...
Read ArticlePaul Hopper is an Australian biotech entrepreneur who has been associated with a number of biotechno...
Read ArticleBiopharmaceutical company Imugene is looking to raise up to $24.6 million in an equity raising targe...
Read ArticleThe company’s securities are in a trading halt until Monday, December 2, or when an announcement is...
Read ArticleIt can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve smal...
Read ArticleIn a recent ASX update, Australian headquartered Imugene Limited (ASX: IMU) has notified that CF33 o...
Read ArticleCF33 is a highly potent, chimeric oncolytic poxvirus – a poxvirus refers to a large group of DNA vir...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Pr...
Read ArticleThe company’s vision is to help transform and improve the treatment of cancer and the lives of the m...
Read ArticleImugene Limited (ASX: IMU) jumped 18 per cent on ASX following the completion of oncolytic virus CF3...
Read Article“We are delighted to be able to complete the acquisition of Vaxinia Pty Ltd and City of Hope licence...
Read ArticleClinical-stage biotech player Imugene Limited (ASX: IMU) soared ~27 per cent on the ASX today, settl...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAustralian immuno-oncology company, Imugene Limited (ASX: IMU) is developing a pipeline of mimotope-...
Read ArticleImugene is planning two separate Phase 1 clinical trials in 2020 to test a CheckVacc construct and a...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read ArticleBiotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno...
Read ArticleAs per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have re...
Read ArticleThe proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imu...
Read ArticleClinical stage immuno-oncology company Imugene (ASX:IMU) has announced that City of Hope res...
Read ArticleASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on...
Read ArticleThe grant focuses on the area of gastric cancer, a disease that disproportionately affects US milita...
Read ArticleImmuno-oncology company Imugene’s (ASX: IMU) oncolytic virotherapy (OV) drug will receive a boost af...
Read ArticleBotanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical t...
Read ArticleA US Department of Defense Grant titled Discovery of Immune Biomarkers That Predict Response to a No...
Read ArticleAs the market players are aware, performance of broader Australian markets is expected to be influen...
Read ArticleAustralia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the d...
Read ArticleTwo separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a V...
Read ArticleDrug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyond...
Read ArticleImugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development pl...
Read ArticleA pioneer in the operating room and in the laboratory, Dr Fong, The Sangiacomo Family Chair in Surgi...
Read ArticleAustralian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is engaged...
Read ArticleInventor Ursula Wiedermann and investigators Tanios Bekaii-Saab and Joshua Tobias presented findings...
Read Article“History is bunk!’’ declared industrialist Henry Ford, but unfortunately for the oro-mucosal deliver...
Read ArticleConsidered as one of the most interesting corners of the stock market, biotech stocks hold the abili...
Read ArticleAustralian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is en...
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleDrugs intake in the form of pills, capsules, and tablets are not the most efficient ways of taking m...
Read ArticleImugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development...
Read ArticleImugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focu...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is i...
Read ArticleAn Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks t...
Read ArticleMove over Thomas the Tank Engine – the Oncolytic Express is about to leave the station! The railway...
Read ArticleAn oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) use...
Read ArticleQueenstown is known as the adventure capital of the world. It attracts over three million people per...
Read ArticleImugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV...
Read ArticleAn Australian-based biotechnology company, Imugene Limited (ASX: IMU) focuses on the development of...
Read ArticleA biotech company headquartered in Australia, Imugene Limited (ASX: IMU) develops new and novel immu...
Read ArticleAustralian immuno-oncology company Imugene (ASX:IMU) has boosted its investigational portfol...
Read ArticleA phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across...
Read ArticleA biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) de...
Read ArticleHealth and medical industry of Australia focuses on the world’s leading technology, advanced researc...
Read ArticleHER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, l...
Read ArticleAn Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a...
Read ArticleThe movement of global stock markets is very sensitive to the news which is associated with the trad...
Read ArticleImugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia th...
Read ArticleImugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all...
Read ArticleImugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field a...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
